Document:

Document

Exhibit 10.5

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE OLO INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO OLO INC. IF PUBLICLY DISCLOSED

AMENDMENT TO THE RESTATED DELIVERY NETWORK AGREEMENT
Effective Date: July 30, 2021

This Amendment to the Restated Delivery Network Agreement (this “Amendment”)  by and between Olo Inc. f/k/a Mobo Systems, Inc (“Olo”) and DoorDash, Inc. (“DoorDash”) is hereby entered into effective as of the Effective Date set forth above between. Capitalized terms used but not defined in this Amendment have the meanings given to those terms in the Agreement.  

WHEREAS, on April 22, 2021, Olo and DoorDash entered into the Restated Delivery Network Agreement (as amended, supplemented, and modified from time to time, the “Agreement”); and

WHEREAS, the parties wish to modify or amend the terms of the Agreement as set forth in this Amendment.

The parties agree as follows:

A.Changes. Pursuant to Section P(8) (Amendment/Modifications) of the Agreement which requires amendments to be made in writing, the parties hereby agree that the “Targeted Availability” column of Exhibit B (Mutual Product Commitments), [***] of the Agreement which currently reads “[***]” shall be deleted and the following inserted in lieu thereof:

“[***]”

B.Fees. Notwithstanding anything to the contrary in Section G(1) (Fees) of the Agreement, and notwithstanding the fact that [***], (i) Olo shall not [***].

C.Conflicts. In the event of any conflict between this Amendment and the Agreement, this Amendment shall control.

D.No Other Changes.  Except as specifically set forth herein, there are no other modifications to the Agreement and all obligations outlined in the Agreement are in full force and effect. This Amendment may be modified or amended only by a separate writing signed by Olo and DoorDash expressly so modifying or amending this Amendment

E.Entire Agreement. The Agreement and this Amendment constitute the entire and complete understanding of the parties regarding its subject matter, and supersede all written agreements and understandings between the parties regarding its subject matter.  Except as expressly amended and supplemented hereby, the Agreement shall remain in full force and effect. 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE OLO INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO OLO INC. IF PUBLICLY DISCLOSED

ACCEPTED AND AGREED:

DOORDASH, INC.        OLO INC
By: /s/ Brian Busovsky                                                      By: /s/ Shalin Sheth_____________
Name: Brian Busovsky                                   Name: Shalin Sheth_____________
Title: Senior Manager, Drive                         Title: VP & GM, Dispatch________
Date: July 30, 2021 ______________                   Date: July 30, 2021______________

2Document

Exhibit 10.6

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE OLO INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO OLO INC. IF PUBLICLY DISCLOSED

SECOND AMENDMENT TO THE RESTATED DELIVERY NETWORK AGREEMENT

Effective Date: April 4, 2022     

This Second Amendment to the Restated Delivery Network Agreement (this “Second Amendment”) by and between Olo Inc. f/k/a Mobo Systems, Inc. (“Olo”) and DoorDash, Inc. (“DoorDash”) is hereby entered into effective as of the Effective Date set forth above. Capitalized terms used but not defined in this Amendment have the meanings given to those terms in the Agreement (as defined below).  

WHEREAS, on April 22, 2021, Olo and DoorDash entered into the Restated Delivery Network Agreement (as amended, supplemented, and modified from time to time, the “Agreement”); 

WHEREAS, on July 30, 2021, Olo and DoorDash entered into the Amendment to the Restated Delivery Network Agreement; and

WHEREAS, the parties wish to further modify or amend the terms of the Agreement as set forth in this Amendment.

The parties agree as follows:

A.Pursuant to Section P(8) (Amendment/Modifications) of the Agreement which requires amendments to be made in writing, the parties hereby agree that the following shall be added to the end of Section E(2) of the Agreement (“DoorDash Obligations”):

“In the event DoorDash responds affirmatively to a Merchant’s request for delivery by DoorDash’s independent delivery providers, and the Product contained in such delivery includes [***].”

B.Pursuant to Section P(8) (Amendment/Modifications) of the Agreement which requires amendments to be made in writing, the parties hereby agree that the following shall be added to Section E(1) (“Olo Obligations”):
     
“Olo shall send DoorDash a [***] report containing a list of all Olo Merchants that sign up for the Delivery Services [***], including those Merchants that desire to use the Delivery Services for Products including [***]. The parties agree that DoorDash will enable Delivery Services for Products [***] for such Merchants only [***].”

C.Conflicts. In the event of any conflict between this Second Amendment and the Agreement, this Second Amendment shall control.

D.No Other Changes.  Except as specifically set forth herein, there are no other modifications to the Agreement and all obligations outlined in the Agreement are in full force and effect. This Second Amendment may be modified or amended only by a separate writing signed by Olo and DoorDash expressly modifying or amending this Second Amendment.

E.Entire Agreement. The Agreement and this Second Amendment constitute the entire and complete understanding of the parties regarding its subject matter, and supersede all written agreements and understandings between the parties regarding its subject matter.  Except as expressly amended and supplemented hereby, the Agreement shall remain in full force and effect. 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE OLO INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO OLO INC. IF PUBLICLY DISCLOSED

ACCEPTED AND AGREED:

DOORDASH, INC.        OLO INC
By: /s/ Brian Busovsky                                                      By: /s/ Shalin Sheth_____________
Name: Brian Busovsky                                   Name: Shalin Sheth_____________
Title: Senior Manager, Drive                         Title: VP & GM, Dispatch________
Date: April 4, 2022 ______________                   Date: April 4, 2022 ______________

2Exhibit
10.3

 

SPECIFIC
TERMS IN THIS AGREEMENT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE

BOTH
NOT MATERIAL AND ARE OF A TYPE THAT ABEONA THERAPEUTICS INC. TREATS AS

CONFIDENTIAL.
THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT AT THE

APPROPRIATE
PLACE WITH THREE ASTERISKS [***]

 

LICENSE
AGREEMENT

 

BETWEEN

 

ULTRAGENYX
PHARMACEUTICAL INC.

 

AND

 

ABEONA
THERAPEUTICS INC.

 

May
16, 2022

 

    	 

    	 

    

 

TABLE
OF CONTENTS

 

	 	Page
	 	 
	ARTICLE 1 DEFINITIONS	1
	ARTICLE 2 LICENSE GRANTS	13
	ARTICLE 3 TRANSITION MATTERS; TECHNOLOGY TRANSFER	15
	ARTICLE 4 DEVELOPMENT, REGULATORY, MANUFACTURE AND
    COMMERCIALIZATION	17
	ARTICLE 5 JOINT TRANSITION TEAM	19
	ARTICLE 6 FINANCIAL PROVISIONS	21
	ARTICLE 7 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION
    AND RELATED MATTERS	25
	ARTICLE 8 CONFIDENTIALITY AND PUBLICITY	29
	ARTICLE 9 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS	31
	ARTICLE 10 INDEMNIFICATION; DAMAGES	35
	ARTICLE 11 LIMITATION OF LIABILITY	36
	ARTICLE 12 TERM AND TERMINATION	37
	ARTICLE 13 DISPUTE RESOLUTION	39
	ARTICLE 14 MISCELLANEOUS	40

 

Schedules

 

	Schedule 1.42	Existing Vendor Agreements
	Schedule 1.72	Licensed Patents
	Schedule 3.1.2	Transition Plan
	Schedule 3.1.4	Transition Costs
	Schedule 3.3	Initial Transfer of Licensed Know-How
	Schedule 4.1.3	Prior Development Costs
	Schedule 8.2	Press Release
	Schedule 9.2.5	Absence of Litigation

 

    	-i-

    	 

    

 

THIS
LICENSE AGREEMENT (this “Agreement”) is entered into as of May 16, 2022 (the “Effective Date”)
by and between Abeona Therapeutics Inc., a Delaware corporation having its principal place of business at 1330 Avenue of the Americas,
33rd Fl, New York, New York 10019, United States (“Abeona”), and Ultragenyx Pharmaceutical Inc.,
a Delaware corporation having offices at 60 Leveroni Court, Novato, California 94949, United States (“Ultragenyx”).

 

INTRODUCTION

 

WHEREAS,
Abeona Controls certain Patents, Know-How and other intellectual property rights related to ABO-102, a proprietary AAV gene therapy for
the treatment of MPS IIIA;

 

WHEREAS,
Abeona and Ultragenyx are parties to that certain Assignment Agreement, dated as of the date hereof, pursuant to which Abeona agreed
to assign to Ultragenyx the Nationwide Children’s Agreement and certain rights and obligations of Abeona thereunder related to
the development and manufacture of ABO-102 (the “Assignment Agreement”); and

 

WHEREAS,
Ultragenyx wishes to obtain from Abeona and Abeona wishes to grant to Ultragenyx certain rights and licenses under certain Patents, Know-How,
and other intellectual property rights Controlled by Abeona to Develop, Manufacture, and Commercialize ABO-102 and associated Licensed
Products in the Territory, subject to the terms and conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree
as follows:

 

ARTICLE
1

DEFINITIONS

 

The
following terms used in this Agreement will have the meanings set forth in this ARTICLE 1:

 

1.1 “AAA”
has the meaning set forth in Section 13.4.

 

1.2 “AAV”
means adeno-associated virus.

 

1.3 “Abeona”
has the meaning set forth in the preamble.

 

1.4 “Abeona
Indemnified Party” has the meaning set forth in Section 10.1.

 

1.5 “Abeona
Sole Inventions” has the meaning set forth in Section 7.1.2.

 

1.6 “ABO-102”
means the product identified in Investigational New Drug Application (IND) 016850, Serial Submission 0034 - Date of Submission: 13 February
2020 pages 4-6.

 

1.7 “Accounting
Standards” means, with respect to a Party or its Affiliate or Sublicensee, in conformance with U.S. GAAP, as such Party, Affiliate
or Sublicensee uses for its financial reporting obligations, consistently applied.

 

1.8 “Action”
means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity,
whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to,
from, by or before any Governmental Authority.

 

    	 

    	 

    

 

1.9 “Affiliate”
means, as of any point in time and for so long as such relationship continues to exist with respect to any Person, any other Person that
controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another Person if,
at the time of such determination, it (a) owns or controls, directly or indirectly, more than fifty percent (50%) of the equity securities
of the subject Person entitled to vote in the election of directors (or, in the case of a Person that is not a corporation, for the election
of the corresponding managing authority), or (b) possesses, directly or indirectly, the power to direct or cause the direction of the
management or policies of such Person (whether through ownership of securities or other ownership interests, by contract or otherwise).

 

1.10 “Agreement”
has the meaning set forth in the preamble.

 

1.11 “Applicable
Law” means any applicable federal, state, local, municipal, foreign, or other law, statute, legislation, constitution, principle
of common law, code, treaty, ordinance, regulation, rule, or order of any kind whatsoever put into place under the authority of any Governmental
Authority, including the FFDCA, PHSA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. §335a
et seq.), U.S. Patent Act (35 U.S.C. §1 et seq.), Federal Civil False Claims Act (31 U.S.C. §3729 et seq.), and the Anti-Kickback
Statute (42 U.S.C. §1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance
promulgated thereunder. For the avoidance of doubt, “Applicable Law” will include the applicable regulations and guidance
of the FDA and EMA (and national implementations thereof) that constitute GLP, GMP, and GCP (and, if and as appropriate under the circumstances,
ICH guidance or other comparable regulation and guidance of any applicable Governmental Authority).

 

1.12 “Assignment
Agreement” has the meaning set forth in the recitals hereto.

 

1.13 “Auditor”
has the meaning set forth in Section 6.9.1.

 

1.14 “Bankrupt
Party” has the meaning set forth in Section 2.6.

 

1.15 “Bankruptcy
Code” has the meaning set forth in Section 2.6.

 

1.16 “Biosimilar
Application” has the meaning set forth in Section 7.2.4(c).

 

1.17 “Biosimilar
Product” means any biological product sold by a Third Party not authorized by Ultragenyx or its Affiliates or its or their
Sublicensees that obtained Regulatory Approval for use in such country through an application or submission filed with the applicable
Regulatory Authority pursuant to a process governing approval of biologics biosimilar to or interchangeable with a Licensed Product or
otherwise relying on the approval of such Licensed Product in such country, including an application filed under 42 U.S.C. § 262(k)
in the United States or any similar provisions in a country outside the United States that rely, at least in part, on the Regulatory
Approval of, or the data submitted in connection with a Regulatory Approval of, such Licensed Product.

 

1.18 “BLA”
means a Biologics License Application filed with the FDA in the United States, as defined in Title 21 of the U.S. Code of Federal Regulations,
Section 601.2, or any non-U.S. counterpart of the foregoing.

 

1.19 “Blocking
IP” has the meaning set forth in Section 6.4.1.

 

    	2

     

    

 

1.20 “Breaching
Party” has the meaning set forth in Section 12.3.1.

 

1.21 “Business
Day” means a day, other than a Saturday, Sunday or holiday on which banks located in New York are authorized to be closed (as
such holidays are listed on the New York State, Department of Financial Services website (by way of example, www.dfs.ny.gov/industry_guidance/bank_holidays_2022
for Calendar Year 2022)).

 

1.22 “Calendar
Quarter” means each of the three month periods ending on March 31, June 30, September 30, and December 31 of any Calendar Year;
provided, however: (a) the first Calendar Quarter of the Term will extend from the Effective Date to the end of the Calendar Quarter
in which the Effective Date occurs; and (b) the last Calendar Quarter will extend from the beginning of the Calendar Quarter in which
this Agreement expires or terminates until the effective date of such expiration or termination.

 

1.23 “Calendar
Year” means, for the first Calendar Year, the period beginning on the Effective Date and ending on December 31, 2022, and for
each Calendar Year thereafter each twelve (12)-month period commencing on January 1, and ending on December 31, except that the last
Calendar Year will commence on January 1 of the year in which this Agreement expires or terminates and end on the effective date of such
expiration or termination.

 

1.24 “Change
of Control” means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party that results in
the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been
converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of the surviving entity or the
parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in
which a Third Party, together with its Affiliates, becomes the beneficial owner of more than fifty percent (50%) of the combined voting
power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of
such Party’s business to which the subject matter of this Agreement relates.

 

1.25 “Clinical
Data” means the original human subject data and case report forms (CRFs) collected or generated with respect to Clinical Studies
of any Licensed Product, together with all analysis, reports, and results with respect thereto.

 

1.26 “Clinical
Study” means a study in which human subjects or patients are dosed with a product, whether approved or investigational, pursuant
to a prospectively defined clinical trial protocol.

 

1.27 “CMO”
means any Third Party contract manufacturing organization.

 

1.28 “Combination
Product” has the meaning set forth in Section 1.82.

 

1.29 “Commercialize”
means, in respect of a Licensed Product, to (a) market, advertise, promote, detail, distribute, offer for sale, sell, have sold, import,
have imported, export, have exported or otherwise exploit, (b) conduct activities, other than Development and Manufacturing, in preparation
for the foregoing activities, including obtaining Pricing and Reimbursement Approval, (c) conduct post-Regulatory Approval commitments
or studies, or (d) conduct other activities in connection with the foregoing activities, including activities related to medical affairs
matters, sales force matters, and pharmacovigilance matters. Cognates of the word “Commercialize” will have correlative meanings.

 

    	3

     

    

 

1.30 “Commercially
Reasonable Efforts” means, with respect to each Party, such efforts that are consistent with the efforts and resources normally
used by a biopharmaceutical company that is of comparable size and scope to such Party in the exercise of its reasonable business discretion
relating to a research and development program or pharmaceutical product owned by it or to which it has exclusive rights, with similar
characteristics as a Licensed Product, which is of similar market potential at a similar stage in its development or product life as
a Licensed Product, taking into account issues of patent coverage, safety and efficacy, product profile, the competitiveness of the marketplace,
the proprietary position, the regulatory structure involved, profitability (including pricing and reimbursement status achieved or projected
to be achieved), and other relevant factors, including technical, legal, scientific or medical factors. For purposes of clarity, it is
anticipated that the level of effort may be different for different markets and may change over time, reflecting changes in the status
of the product and the market(s) involved.

 

1.31 “Confidential
Information” means (a) all trade secrets or confidential or proprietary information (including any tangible materials embodying
any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed to the other Party or any of its Affiliates in
connection with this Agreement, (b) “Confidential Information” (as defined in the Prior CDA) that was disclosed by a Party
or any of its Affiliates to the other Party or any of its Affiliates under the Prior CDA, and (c) the terms and conditions of this Agreement;
provided, however, that Confidential Information will not include information that:

 

(i) becomes
part of the public domain through no breach of this Agreement on the part of the receiving Party;

 

(ii) was
in the receiving Party’s possession prior to disclosure by the disclosing Party hereunder, and not through a prior disclosure by
the disclosing Party, without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party’s
or such Affiliate’s written records or other competent evidence);

 

(iii) is
subsequently received by the receiving Party from a Third Party who is not known by the receiving Party to be under an obligation of
confidentiality to the disclosing Party under any agreement between such Third Party and the disclosing Party; or

 

(iv) has
been independently developed by or for the receiving Party without reference to, or use or disclosure of, the disclosing Party’s
Confidential Information (as evidenced by the receiving Party’s or such Affiliate’s written records or other competent evidence);

 

provided,
further, that clauses (ii) through (iv) above will not apply to the terms and conditions of this Agreement.

 

1.32 “Control”
or “Controlled” means, with respect to any Know-How, Patent, Regulatory Material, Regulatory Approval or other property
right, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or otherwise)
of a Person or its Affiliate, to grant access, a license or a sublicense of or under such Know-How, Patent, Regulatory Material, Regulatory
Approval or other property right without (a) breaching the terms of any agreement with a Third Party and (b) paying any consideration
to any Third Party, except for that which a Party in-licenses and is included within the Licensed Technology as contemplated in Section
6.4.1. Notwithstanding anything in this Agreement to the contrary, a Party will be deemed not to Control any Know-How, Patent, Regulatory
Material, Regulatory Approval or other property right that is owned or in-licensed by an acquirer of such Party, except (i) with respect
to any such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right arising from participation by employees
or consultants of such acquirer in furtherance of this Agreement after the relevant Change of Control, (ii) to the extent that any such
Know-How, Patent, Regulatory Material, Regulatory Approval or other property right is included in or used in furtherance of the this
Agreement by the acquirer after such Change of Control, or (iii) for intellectual property rights constituting improvements (or direct
improvements to such improvements) to the Know-How or Patents Controlled by the other Party that are specific to a product in the Field,
in each case, conceived, discovered, developed or otherwise made by any employees or consultants of the acquirer after such Change of
Control but during the Transition Period.

 

    	4

     

    

 

1.33 “Cover,”
“Covering” or “Covered” means, when referring to a Licensed Product: (a) with respect to a Patent,
that, in the absence of a license granted to a Person under an issued claim included in such Patent, the practice by such Person of a
specified activity with respect to such Licensed Product would infringe such claim, or (b) with respect to an application for Patents,
that, in the absence of a license granted to a Person under a claim included in such application, the practice by such Person of a specified
activity with respect to such Licensed Product would infringe such claim if such patent application were to issue as a patent.

 

1.34 “Development”
means, with respect to a Licensed Product, all (a) non-clinical and pre-clinical discovery, research and development activities and optimization
completed prior to filing an IND with respect to such Licensed Product, including animal and toxicology studies, and (b) clinical and
non-clinical research and development activities conducted after filing of an IND with respect to such Licensed Product, including toxicology,
pharmacology test method development and stability testing, process development, formulation development, delivery system development,
quality assurance and quality control development, statistical analysis, Clinical Studies, regulatory affairs, pharmacovigilance, Clinical
Study regulatory activities and obtaining and maintaining Regulatory Approval. Cognates of the word “Development” will have
correlative meanings.

 

1.35 “Disputes”
has the meaning set forth in Section 13.1.

 

1.36 “Distributor”
means any Third Party appointed by Ultragenyx or any of its Affiliates or its or their Sublicensees to Commercialize Licensed Product
in one or more countries in the Territory, in circumstances where such Third Party purchases its requirements of Licensed Product from
Ultragenyx or its Affiliates or its or their Sublicensees and such Third Party does not pay Ultragenyx or any of its Affiliates or its
or their Sublicensees consideration based on such Third Party’s resales.

 

1.37 “Dollars”
or “US$” means United States dollars.

 

1.38 “Effective
Date” has the meaning set forth in the preamble.

 

1.39 “EMA”
means the European Medicines Agency or any successor agency thereto.

 

1.40 “Executive
Officers” has the meaning set forth in Section 13.3.

 

1.41 “Existing
Vendor” means any Third Party that is a counterparty to an Existing Vendor Agreement.

 

1.42 “Existing
Vendor Agreements” means the agreements set forth on Schedule 1.42.

 

1.43 “Expedited
Arbitration” has the meaning set forth in Section 13.4.

 

1.44 “Expedited
Dispute” has the meaning set forth in Section 13.4.

 

    	5

     

    

 

1.45 “Exploit”
means to make, have made, use, distribute, offer for sale, sell, import or export, including to research, develop, modify, enhance, improve,
register, distribute, commercialize, or otherwise dispose of. Cognates of the word “Exploit” will have correlative meanings.

 

1.46 “External
Costs” means, with respect to a Party, costs and expenses paid by such Party or its Affiliates to Third Parties (or payable
to Third Parties and accrued in accordance with Accounting Standards), other than employees of such Party or its Affiliates. For clarity,
with respect to Transition Costs, External Costs will include lease payments for shared work space in Spain, travel, general laboratory
or office supplies, and all other general and administrative Third Party costs and expenses and overhead items, in each case, to the
extent invoiced by a Third Party to a Party.

 

1.47 “FDA”
means the United States Food and Drug Administration or any successor agency thereto.

 

1.48 “FFDCA”
means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), as amended from time to time, together with any
rules, regulations, and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).

 

1.49 “Field”
means the treatment, palliation, diagnosis, cure or prevention of MPS IIIA in humans.

 

1.50 “First
Commercial Sale” means, on a Licensed Product-by-Licensed Product basis, the first sale of such Licensed Product by a Selling
Party to a Third Party resulting in Net Sales; provided that any sale of a Licensed Product to an Affiliate or Sublicensee will not constitute
a First Commercial Sale. First Commercial Sale includes the first such sale to a Third Party for patient assistance, named patient use,
or other similar programs or studies for which a Selling Party receives Net Sales.

 

1.51 “FTE”
means the equivalent of a full-time individual’s work, performed by one or more employees, at [***] hours per year for a twelve-month
period, carried out by an appropriately qualified employee of a Party or its Affiliates performing activities pursuant to this Agreement.
Overtime, and work on weekends, holidays and the like will not be counted with any multiplier (e.g., time- and-a-half or double time)
toward the number of hours that are used to calculate the FTE contribution. For clarity, Third Party contractors or indirect personnel
(including support functions such as managerial, financial, legal or business development) will not constitute FTEs.

 

1.52 “FTE
Costs” means, for any period, the FTE Rate multiplied by the number of FTEs who perform a specified activity under this Agreement.
FTEs will be pro-rated as necessary.

 

1.53 “FTE
Rate” means, (a) for individuals in the US, the rate of [***] Dollars ($[***]) per one full FTE per calendar month, and (b)
for individuals outside the US, the rate of [***] Dollars ($[***]) per one full FTE per calendar month. The FTE Rate will be prorated
on a daily basis as necessary. For clarity, such FTE Rate includes the cost of salaries, benefits, and insurance. Infrastructure costs,
travel, general laboratory or office supplies, training, and all other general and administrative expenses and overhead items are not
included within the FTE Rate.

 

    	6

     

    

 

1.54 “GCP”
or “Good Clinical Practice” means all applicable then-current standards for the design, conduct, performance, monitoring,
auditing, recording, analyses and reporting of Clinical Studies, including, as applicable, (a) as set forth in the ICH Guideline for
Good Clinical Practice and any other ICH guidelines for good clinical practice for Clinical Studies on medicinal products, (b) the Declaration
of Helsinki (2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications
thereto, (c) as set forth in the FFDCA and as promulgated in FDA regulations, including 21 C.F.R. Parts 11 (Electronic Records and Signatures),
50 (Protection of Human Subjects), 54 (Financial Disclosure by Clinical Investigators), 56 (Institutional Review Boards) and 312 (Investigational
New Drug Application), and (d) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time
to time and in each case, that provide for, among other things, assurance that Clinical Data and reported results are credible and accurate
and the manner in which Clinical Studies are conducted protects the rights, integrity, and confidentiality of Clinical Study subjects.

 

1.55 “GLP”
or “Good Laboratory Practice” means all applicable then-current standards for good laboratory practices, as set forth
in the FDA’s Good Laboratory Practice regulations in 21 C.F.R. Part 58, and such standards of good laboratory practice as are required
by the equivalent Applicable Law in the relevant country and other organizations and Governmental Authorities in countries in which a
Licensed Product is intended to be sold by the Party that is subject to such standards.

 

1.56 “GMP”
or “Good Manufacturing Practice” means all applicable then-current standards for good manufacturing practices, including,
as applicable, (a) the principles set forth in the FDA’s Current Good Manufacturing Practices regulations in 21 C.F.R. §§
210, 211, 600 and 610 and all other applicable FDA guidelines and requirements, (b) European Directive 2003/94/EC principles and guidelines
of good manufacturing practice for medicinal products and investigational medicines for human use and all other applicable guidelines
stated in the EudraLex guidelines relating to manufacturing of medicinal products, (c) manufacturing principles detailed in applicable
ICH guidelines, and (d) all equivalent Applicable Law applicable to Manufacturing in any relevant country, each as may be amended and
applicable from time to time.

 

1.57 “Government
Official” (where “government” means all levels and subdivisions of governments, i.e., local, regional, national,
administrative, legislative, executive, or judicial, and royal or ruling families) means: (a) any officer or employee of a government
or any department, agency or instrumentality of a government (which includes public enterprises, and entities owned or controlled by
the state); (b) any officer or employee of a public international organization such as the World Bank or United Nations; (c) any officer
or employee of a political party, or any candidate for public office; (d) any person defined as a government or public official under
local Applicable Law and not already covered by any of the above; and (e) any person acting in an official capacity for or on behalf
of any of the above. “Government Official” will include any person with close family members who are Government Officials
(as defined above) with the capacity, actual or perceived, to influence or take official decisions affecting a Party’s business.

 

1.58 “Governmental
Authority” means any multinational, federal, national, state, provincial, local or other entity, office, commission, bureau,
agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or
officer, exercising executive, judicial, legislative, police, regulatory, administrative or taxing authority or functions of any nature
pertaining to government.

 

1.59 “ICH”
means the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

 

1.60 “IND”
means an Investigational New Drug application, clinical trial application or similar application or submission for approval to conduct
human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirement of such Regulatory
Authority, and any amendments or supplements thereto.

 

1.61 “Indemnified
Party” has the meaning set forth in Section 10.3.

 

    	7

     

    

 

1.62 “Indemnifying
Party” has the meaning set forth in Section 10.3.

 

1.63 “Infringement”
has the meaning set forth in Section 7.3.1.

 

1.64 “Infringement
Action” has the meaning set forth in Section 7.3.2.

 

1.65 “Infringement
Claim” has the meaning set forth in Section 7.4.

 

1.66 “Inventory”
means all quantities of finished Licensed Product, or work in progress, in the possession or Control of Abeona or any of its Affiliates
as of the Effective Date.

 

1.67 “Joint
Inventions” has the meaning set forth in Section 7.1.3.

 

1.68 “Joint
Patents” means the Patents Covering the Joint Inventions.

 

1.69 “Joint
Transition Team” or “JTT” has the meaning set forth in Section 5.1.1.

 

1.70 “Know-How”
means all Materials, inventions, practices, methods, protocols, formulae, knowledge, improvements, know-how, trade secrets, quality assurance,
quality control, analytical test methods, processes, procedures, assays, skills, experience, techniques, technology, information, data
and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical
and quality control data, patentable or otherwise.

 

1.71 “Licensed
Know-How” means any and all Know-How relating to any Licensed Product that is (a) Controlled by Abeona or its Affiliates as
of the Effective Date, in each case, that is necessary or useful to Exploit any Licensed Product in the Field and in the Territory or
(b) an Abeona Sole Invention that is described in clause (ii) of the definition thereof.

 

1.72 “Licensed
Patents” means (a) the patent applications listed in Schedule 1.72 attached hereto, plus (i) all divisionals, continuations,
continuations-in-part thereof or any other patent rights claiming priority directly or indirectly to any of the issued patents or patent
applications identified on Schedule 1.72, and (ii) all patents issuing on any of the foregoing, together with all registrations,
reissues, re-examinations, renewals, supplemental protection certificates and extensions of any of the foregoing, and all foreign counterparts
thereof, (b) any other Patents, existing as of the Effective Date, Controlled by Abeona or its Affiliates or that are Joint Patents,
in each case, that (i) claim the composition of matter, manufacture or use of any Licensed Product (including use as a monotherapy or
in combination with other compositions of matter), or (ii) are necessary or useful for the research, Development, Manufacture, import,
export, use, sale or Commercialization of any Licensed Products in the Field in the Territory, and (c) any Patents that claim Licensed
Know-How existing as of the Effective Date that are filed with a patent office or relevant Governmental Authority after the Effective
Date.

 

1.73 “Licensed
Product” means any pharmaceutical product in final form containing: (a) ABO-102 or (b) any modification, enhancement or derivative
of ABO-102, in each case ((a) and (b)), whether alone as the sole active component or as a combination with other active components,
in any presentation, formulation or dosage form. For clarification, Licensed Product will include any Combination Product (provided,
that no licenses granted by Abeona under Section 2.1 shall apply to any active components in a Combination Product other than ABO-102
or any modification, enhancement or derivative of ABO-102).

 

1.74 “Licensed
Technology” means collectively, Licensed Patents, Licensed Know-How and Abeona’s interest in Joint Inventions and Joint
Patents.

 

    	8

     

    

 

1.75 “Losses”
means damages, losses, liabilities, costs (including costs of investigation and defense), fines, penalties, taxes, expenses, or amounts
paid in settlement (in each case, including reasonable attorneys’ and experts’ fees and expenses), in each case resulting
from an Action.

 

1.76 “Manufacture”
or “Manufacturing” means activities directed to making, having made, producing, manufacturing, analytical development,
processing, formulating, filling, finishing, packaging, labeling, quality control testing and quality assurance release, shipping or
storage of a Licensed Product by or on behalf of a Selling Party. References to a Person engaging in Manufacturing activities will include
having any or all of the foregoing activities performed by a Third Party.

 

1.77 “Materials”
means all tangible compositions of matter, devices, articles of manufacture, assays, biological, chemical, or physical materials, and
other similar materials.

 

1.78 “Milestone
Event” has the meaning set forth in Section 6.1.

 

1.79 “Milestone
Payment” has the meaning set forth in Section 6.1.

 

1.80 “MPS
IIIA” means Mucopolysaccharidosis type III A, which is also referred to as “Sanfilippo syndrome type A”.

 

1.81 “Nationwide
Children’s Agreement” means the Exclusive License Agreement, by and between Nationwide Children’s Hospital (“Nationwide
Children’s”) and Abeona, effective as of November 8, 2013, as amended or restated from time to time.

 

1.82 “Net
Sales” means, with respect to the Licensed Products, the gross amount received for all sales of such Licensed Products by Ultragenyx
and its Affiliates and Sublicensees (each, a “Selling Party”) to a Third Party (other than another Selling Party,
unless such Selling Party is the end user of such Licensed Product), less the following deductions actually incurred or paid or otherwise
accrued, allowed, reserved or allocated in accordance with Ultragenyx’s Accounting Standards:

 

	 	(a)	normal and
    customary trade, cash and quantity discounts, allowances and credits for such Licensed Products;
	 	 	 
	 	(b)	fees paid, reserves, and
    allowances to distributors and discounts (including cash, quantity and patient program discounts), charge-back payments, rebates
    and similar payments granted to customers, wholesalers, distributors, buying groups, retailers, health care insurance carriers, pharmacy
    benefit management companies, health maintenance organizations, managed health care organizations or to federal, state and local
    governments, their agencies, and purchasers and reimbursers or to trade customers;
	 	 	 
	 	(c)	clawbacks of any payments
    made to a Selling Party;
	 	 	 
	 	(d)	credits or allowances actually
    granted for price adjustments (including retroactive price adjustments), damaged goods, spoiled product, claims, recalls, rejections
    or returns of such Licensed Products, including such Licensed Products returned in connection with withdrawals;
	 	 	 
	 	(e)	freight out, postage, customs
    charges, shipping and insurance charges for delivery of such Licensed Products; and
	 	 	 
	 	(f)	taxes or duties levied
    on, absorbed by, or otherwise imposed on the sale of such Licensed Products, including value-added taxes, or other governmental charges
    otherwise imposed upon the billed amount, as adjusted for rebates and refunds, to the extent not paid by the Third Party, but excluding
    any income taxes.

 

    	9

     

    

 

The
following will not give rise to Net Sales: any dispositions of any Licensed Products for pre-clinical or clinical testing required in
connection with obtaining Regulatory Approval or Pricing and Reimbursement Approval of any Licensed Products nor any dispositions or
use of any Licensed Products under compassionate use, patient assistance, named patient use, or other similar programs or studies where
the Licensed Product is supplied without charge or below manufacturing cost.

 

In
the event that a Licensed Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product
will be adjusted by multiplying actual Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition
of “Net Sales” by the fraction A/(A+B), where A is the average net selling price in such country of the relevant Licensed
Product if sold separately in such country and B is the average net selling price in such country of, as applicable, each product that
contains the Other Items contained in such Combination Product if sold separately in such country. If either such Licensed Product or
the relevant Other Item(s) is not sold separately (including in the case of the sale of a combination therapy that contains the Licensed
Product but is not sold separately) in a particular country, then the adjustment to Net Sales will be determined by the Parties in good
faith to reasonably reflect the fair market value of the contribution of such Licensed Product or product in such Combination Product
to the total fair market value of such Combination Product.

 

In
the case of pharmacy incentive programs, hospital performance incentive programs, chargebacks, disease management programs, similar programs
or discounts on portfolio product offerings, all rebates, discounts and other forms of reimbursements will be allocated among products
on the basis on which such rebates, discounts and other forms of reimbursements were actually granted or, if such basis cannot be determined,
in accordance with Ultragenyx’s, its Affiliates’ or its or their Sublicensees’ existing allocation method; provided
that any such allocation will be done in accordance with Applicable Law, including any price reporting laws, rules and regulations and
such allocation method will not disproportionately reduce Net Sales in favor of net sales of other products.

 

For
the purposes of calculating Net Sales, all Net Sales will be converted into Dollars pursuant to Section 6.12.

 

Subject
to the above, all sales and deductions included within Net Sales will be calculated in accordance with the standard internal policies
and procedures of Ultragenyx, its Affiliates or its or their Sublicensees, which will be in accordance with applicable Accounting Standards.
Notwithstanding anything herein to the contrary, in the event that a Selling Party will receive payment for a Licensed Product on an
installment basis, the Parties will apply the pro-rata amount of the installment received to Net Sales with respect to such Licensed
Product.

 

As
used herein, “Combination Product” means any Licensed Product in combination with one or more Other Items either when
(A) priced and sold in a single package containing such multiple products or (B) packaged separately but sold together for a single price
or where a discount, rebate or other amount is provided in exchange for (or otherwise conditioned upon) the purchase of such Other Item,
in each case ((A) and (B)), including all dosage forms, formulations, presentations, and package configurations. “Other Item”
means any therapeutically active pharmaceutical ingredient other than the therapeutically active pharmaceutical ingredient(s) of the
Licensed Product.

 

1.83 “Other
Item” has the meaning set forth in Section 1.82.

 

1.84 “Non-Breaching
Party” has the meaning set forth in Section 12.3.1.

 

    	10

     

    

 

1.85 “Party”
means either Abeona or Ultragenyx; “Parties” means Abeona and Ultragenyx, collectively.

 

1.86 “Patents”
means the rights and interests in and to (a) all patents and patent applications (including provisional applications), including all
divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations,
registrations, any other pre- or post-grant forms of any of the foregoing, (b) any confirmation patent or registration patent or patent
of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations,
foreign counterparts, and the like of any of the foregoing, (c) any and all patents that have issued or in the future issue from the
foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and
certificates of invention.

 

1.87 “Person”
means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization
or a Governmental Authority.

 

1.88 “Pricing
and Reimbursement Approval” means, with respect to a Licensed Product, the governmental approval, agreement, determination
or decision establishing the price or level of reimbursement for such Licensed Product, in a given country in the Territory prior to
the sale of such Licensed Product in such jurisdiction in the Territory.

 

1.89 “Prior
CDA” means the Mutual Confidential Disclosure Agreement by and between the Parties, dated January 13, 2021, as amended by the
First Amendment, dated February 2, 2022.

 

1.90 “Prior
Development Costs” has the meaning set forth on Schedule 4.1.3.

 

1.91 “Prosecute”
or “Prosecution” means in relation to any Patents, (a) to prepare and file patent applications, including re-examinations
or re-issues thereof, and represent applicants or assignees before relevant patent offices or other relevant Governmental Authorities
during examination, re-examination and re-issue thereof, in appeal processes, interferences, oppositions or any equivalent proceedings,
(b) to defend all such applications against Third Party oppositions or other challenges, (c) to secure the grant of any patents arising
from such patent application, (d) to maintain in force any issued patent (including through payment of any relevant maintenance fees),
and (e) to make all decisions with regard to any of the foregoing activities.

 

1.92 “Public
Health Service Act” or “PHSA” means the United States Public Health Service Act (42 U.S.C. 201 et seq.),
as amended.

 

1.93 “Regulatory
Approval” means, with respect to a particular country or other regulatory jurisdiction, any approval, license, registration
or authorization by the applicable Regulatory Authority necessary for the marketing and sale of a Licensed Product in the Field in such
country, excluding, in each case, separate Pricing and Reimbursement Approval that may be required.

 

1.94 “Regulatory
Authority” means, with respect to a particular country, any multinational, federal, national, state, provincial or local regulatory
agency, department, bureau or other Governmental Authority with authority over the Development, Manufacture, or Commercialization or
granting of Regulatory Approval of a Licensed Product in such country, including, but not limited to, the FDA and EMA.

 

    	11

     

    

 

1.95 “Regulatory
Exclusivity” means, with respect to each Licensed Product in any country in the Territory, any data exclusivity rights, market
exclusivity rights, or other exclusive right (other than Patents exclusivity) granted or afforded by Applicable Law or by a Regulatory
Authority in such country that prevents the approval or marketing of any Biosimilar Product of such Licensed Product in such country,
including reference product exclusivity under Section 351(k)(7)(C) of the PHSA and pediatric exclusivity under Section 351(m) of the
same and any foreign equivalents.

 

1.96 “Regulatory
Materials” means (a) any regulatory application, submission, notification, communication, correspondence, registration, Regulatory
Approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority related to Developing, Manufacturing,
obtaining Regulatory Approval, marketing, selling or otherwise Commercializing a pharmaceutical product in a particular country or jurisdiction,
(b) all supplements and amendments to any of the foregoing, and (c) all data, including Clinical Data, and other information contained
in any of the foregoing.

 

1.97 “ROFR
Negotiation Period” has the meaning set forth in Section 2.6.

 

1.98 “ROFR
Notice” has the meaning set forth in Section 2.6.

 

1.99 “ROFR
Transaction” has the meaning set forth in Section 2.6.

 

1.100 “Royalty
Term” means, on a Licensed Product-by-Licensed Product basis, the period commencing on the date of the First Commercial Sale
of such Licensed Product and ending upon the last of the following to occur: (a) the expiration of the last-to-expire Valid Claim that
Covers such Licensed Product in any country; and (b) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product.

 

1.101 “Selling
Party” has the meaning set forth in Section 1.82.

 

1.102 “Sole
Inventions” has the meaning set forth in Section 7.1.2.

 

1.103 “Sublicense”
means a grant of rights from Ultragenyx to a Sublicensee under any of the rights licensed to Ultragenyx by Abeona under Section 2.1.

 

1.104 “Sublicensee”
means a Person, other than an Affiliate or a Distributor of Ultragenyx, that is granted a sublicense by Ultragenyx or its Affiliates
to the rights granted to Ultragenyx in Section 2.1, as provided in Section 2.3.

 

1.105 “Term”
has the meaning set forth in Section 12.1.

 

1.106 “Territory”
means worldwide.

 

1.107 “Third
Party” means any Person other than a Party or any of its Affiliates.

 

1.108 “Third
Party License” has the meaning set forth in Section 6.4.1.

 

1.109 “Third
Party Losses” means Losses resulting from an Action by a Third Party.

 

1.110 “Transition
Costs” means with respect to a Calendar Quarter, the FTE Costs plus the External Costs actually incurred in connection with
the Transition Services for such Calendar Quarter as set forth in the Transition Plan.

 

    	12

     

    

 

1.111 “Transition
Period” means the period commencing on the Effective Date and ending upon the earlier of (a) the completion of all activities
set forth in the agreed-upon Transition Plan and (b) December 31, 2022. The Transition Period may be extended by mutual written agreement
of both Parties set forth in Section 3.1.1.

 

1.112 “Transition
Plan” has the meaning set forth in Section 3.1.2.

 

1.113 “Transition
Services” has the meaning set forth in Section 3.1.2.

 

1.114 “Ultragenyx”
has the meaning set forth in the preamble.

 

1.115 “Ultragenyx
Indemnified Party” has the meaning set forth in Section 10.1.

 

1.116 “Ultragenyx
Patents” has the meaning set forth in Section 7.1.2.

 

1.117 “Ultragenyx
Sole Inventions” has the meaning set forth in Section 7.1.2.

 

1.118 “United
States” or “U.S.” or “US” means the United States and its territories, possessions and
commonwealths.

 

1.119 “Upstream
Patent” means any Patent exclusively licensed to Abeona under the Nationwide Children’s Agreement (prior to the assignment
of thereof).

 

1.120 “Valid
Claim” means a claim of any issued, unexpired patent within the Upstream Patents, the Licensed Patents or the Joint Patents
that has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable, unpatentable or invalid by a final,
non-appealable decision of a court or other Governmental Authority of competent jurisdiction and has not been admitted to be invalid
or unenforceable through reissue, disclaimer, or otherwise.

 

ARTICLE
2

LICENSE
GRANTS

 

2.1 Exclusive
License Grant. Subject to the terms and conditions of this Agreement, Abeona hereby grants to Ultragenyx an exclusive (even with
respect to Abeona and its Affiliates, subject to Section 2.2), sublicensable (subject to Section 2.3.1), royalty-bearing right and license
under the Licensed Technology, to Exploit Licensed Products in the Field and in the Territory.

 

2.2 Retained
Abeona Rights. Notwithstanding the license granted to Ultragenyx pursuant to Section 2.1, Abeona will retain for itself, and its
Affiliates, the right to practice the Licensed Technology solely to the extent necessary to perform any Transition Services under the
Transition Plan and perform other obligations expressly set forth in this Agreement. For the avoidance of doubt, Abeona will retain the
sole right to practice the Licensed Patents outside of the Field.

 

2.3 Sublicensing
and Subcontracting.

 

2.3.1 Ultragenyx
Right to Sublicense. Ultragenyx will have the right to grant Sublicenses (through multiple tiers) of the rights granted to Ultragenyx
pursuant to Section 2.1 as follows: (a) to its Affiliates; provided such Sublicense only remains in effect for as long as such Sublicensee
remains an Affiliate of Ultragenyx, and (b) to Third Parties, in each case of clause (b), subject to the requirements of Section 2.3.2.

 

    	13

     

    

 

2.3.2 Sublicense
Requirements. Each Sublicense granted by Ultragenyx to a Third Party pursuant to Section 2.3.1 will be subject and subordinate to
the terms and conditions of this Agreement. No Sublicense will materially diminish, reduce or eliminate any obligation of Ultragenyx
under this Agreement. Ultragenyx will ensure that each of its non-Affiliate Sublicensees is bound by a written agreement containing provisions
that are consistent with those contained in this Agreement.

 

2.4 Performance
by Independent Contractors. (a) Ultragenyx may contract or delegate any portion of its obligations or activities hereunder to a Third
Party contractor subject to the terms and condition of Section 14.8 and (b) Abeona may contract or delegate any portion of its obligations
or activities hereunder to a Third Party contractor to the extent set forth in the Transition Plan or with the prior written authorization
of Ultragenyx, in each case ((a) and (b)) provided that, (i) the contractor is appropriately qualified to conduct the activities it is
engaged to conduct under this Agreement; (ii) the contractor undertakes in writing commercially reasonable obligations of confidentiality
and non-use regarding Confidential Information, that are substantially the same as those undertaken by the Parties with respect to Confidential
Information pursuant to ARTICLE 8 hereof (but of shorter duration if customary); and (iii) the contractor undertakes in writing to assign
or exclusively license back (with the right to sublicense) all intellectual property that Ultragenyx deems to be material to the Exploitation
of a Licensed Product that results from performing any such work to the corresponding Party.

 

2.5 Reservation
of Rights. No rights, other than those expressly set forth in this Agreement, are granted to either Party under this Agreement, and
no additional rights will be deemed granted to either Party by implication, estoppel or otherwise, with respect to any intellectual property
rights. All rights not expressly granted by either Party or its Affiliates to the other Party under this Agreement are reserved. Neither
Party nor any of its Affiliates will use or practice any Know-How or Patents licensed or provided to such Party or any of its Affiliates
outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this
Agreement.

 

2.6 Nationwide
Children’s Agreement. Abeona will assign to Ultragenyx all of Abeona’s right, title and interest in and to the Nationwide
Children’s Agreement pursuant to the terms and conditions of the Assignment Agreement. Abeona hereby covenants to Ultragenyx that,
as of the Effective Date, except as provided in Paragraph 30 of the Twelfth Amendment to the Nationwide Children’s Agreement, dated
May 16, 2022, and solely to the extent necessary for its performance of the Transition Services, Abeona will not practice any of the
intellectual property rights that are the subject of the Nationwide Children’s Agreement.

 

2.7 Right
of First Refusal. In the event that Abeona or any Affiliate of Abeona proposes to assign, transfer, license or otherwise grant any
of Abeona’s rights with respect to any Licensed Products under this Agreement to a Third Party, including Abeona’s rights
to receive royalties or other payments for the Commercialization of Licensed Products, but excluding any Change of Control transaction
of Abeona, (such proposed transaction, a “ROFR Transaction”) Ultragenyx will have a right of first refusal to acquire
all rights related to such ROFR Transaction at a valuation, and on such additional terms and conditions, mutually agreed upon by the
Parties. Abeona will provide Ultragenyx with advance written notice of the ROFR Transaction (including a summary of the material terms
and conditions thereof) (a “ROFR Notice”) and allow Ultragenyx [***] days to respond whether Ultragenyx is willing
to acquire all rights relating to or subject to the ROFR Transaction from Abeona (an “Ultragenyx Election Notice”).
Upon the receipt by Abeona of an Ultragenyx Election Notice, the Parties will negotiate in good faith for a period of [***] days (the
“ROFR Terms Negotiation Period”) to finalize the material terms and conditions regarding the acquisition by Ultragenyx
of all rights related to such ROFR Transaction (the “ROFR Term Sheet”). If, after the completion of the ROFR Terms
Negotiation Period, the Parties cannot agree upon the ROFR Term Sheet, Abeona may proceed with the ROFR Transaction as originally proposed
by Abeona in the ROFR Notice, provided that if the ROFR Transaction as originally proposed is not executed within [***] days after the
completion of the ROFR Terms Negotiation Period, any ROFR Transaction will again become subject to Ultragenyx’s right of first
refusal in accordance with this Section 2.7. If the Parties do agree upon the ROFR Term Sheet, the Parties will negotiate in good faith
for a period of [***] days (the “ROFR Negotiation Period”) to finalize and execute definitive agreements regarding
the acquisition by Ultragenyx or all rights related to such ROFR Transaction. If, after the completion of the ROFR Negotiation Period,
the Parties cannot agree to definitive agreements effecting the acquisition by Ultragenyx of all rights related to the ROFR Transaction,
Abeona may proceed with the ROFR Transaction as originally proposed by Abeona in its written notice to Ultragenyx, provided that if the
ROFR Transaction as originally proposed is not executed within [***] days after the completion of the ROFR Negotiation Period, any ROFR
Transaction will again become subject to Ultragenyx’s right of first refusal in accordance with this Section 2.7.

 

    	14

     

    

 

2.8 Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement to Ultragenyx are and will otherwise be deemed to be, for purposes
of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the
Bankruptcy Code. The Parties agree that Ultragenyx and its Affiliates and Sublicensees will retain and may fully exercise all of its
rights and elections under the Bankruptcy Code and any foreign equivalent thereto. The Parties further agree that if (a) a bankruptcy
proceeding by or against Abeona or its Affiliate (the “Bankrupt Party”) is commenced under the Bankruptcy Code, (b)
this Agreement is rejected as provided in the Bankruptcy Code, and (c) Ultragenyx or its Affiliate elects to retain its rights hereunder
as provided in Section 365(n) of the Bankruptcy Code, then Ultragenyx will be entitled to a complete duplicate of, and complete access
to (as Ultragenyx deems appropriate), all intellectual property that is the subject of a right or license granted to Ultragenyx hereunder
and all embodiments of the same. Upon such occurrence, such intellectual property and all embodiments of such intellectual property will
be promptly delivered by the Bankrupt Party to Ultragenyx. The Bankrupt Party (in any capacity, including debtor-in-possession) and its
successors and assigns (including any trustee) hereby agrees not to interfere with the exercise by Ultragenyx of its rights or licenses
to such intellectual property or such embodiments of intellectual property in accordance with this Agreement, and agrees to assist Ultragenyx
and its Affiliates in obtaining such intellectual property or such embodiments of intellectual property in the possession or Control
of Third Parties. The foregoing provisions are without prejudice to any rights Ultragenyx may have arising under the Bankruptcy Code
or other Applicable Law. As used herein, “Bankruptcy Code” means Title 11, United States Code, as from time to time
in effect.

 

ARTICLE
3

TRANSITION
MATTERS; TECHNOLOGY TRANSFER

 

3.1 Transition
Services.

 

3.1.1 Transition
Services. During the Transition Period, Abeona (directly or through its Affiliates or approved Third Party contractors) will perform
certain transition services in connection with Licensed Products (“Transition Services”), as more fully detailed in
the Transition Plan. During the Transition Period, each Party will have the right to propose extensions of the Transition Period; provided
that any proposed extension will be effective only if approved by the Alliance Manager for each Party (e-mail to be sufficient for this
purpose).

 

3.1.2 Transition
Plan. The initial Transition Plan is attached hereto as Schedule 3.1.2. Within [***] days following the Effective Date, the
Parties will update the Transition Plan. Each such plan, as modified, will include (a) a description of the Transition Services, (b)
the proposed timetable for performing such Transition Services, (c) the estimated Transition Costs for completion of such Transition
Services (attached separately as Schedule 3.1.4), (d) the deliverables, (e) the name of any Third Party contractors engaged by
Abeona for the performance of the Transition Services and a description of which activities such contractors will perform and (f) such
other information agreed upon by the Parties (the plan attached hereto as Schedule 3.1.2 and each update thereto in accordance
with this Agreement, the “Transition Plan”). Abeona will use Commercially Reasonable Efforts to complete the Transition
Services assigned to Abeona within the timeframes set forth in the Transition Plan and within the estimated Transition Costs. In the
event of any inconsistency between the Transition Plan and this Agreement, the terms of this Agreement will prevail. During the Transition
Period, each Party will have the right to propose modifications or amendments to the Transition Plan; provided, however that any modifications
or amendments to such Transition Plan that are proposed by either Party will be subject to review and approval by the Joint Transition
Team pursuant to Section 5.1.2.

 

    	15

     

    

 

3.1.3 Transition
Services Reporting. At each meeting of the Joint Transition Team, Abeona will provide an update regarding the Transition Services
it has performed, or caused to be performed, since the previous meeting of the Joint Transition Team, its Transition Services in process,
and the future Transition Services it expects to initiate prior to the next meeting of the Joint Transition Team. Abeona will highlight
any key issues or delays with respect to the Transition Services or any expected issues related to the Transition Costs for joint discussion
and resolution. Abeona will respond to the questions or requests of the Joint Transition Team or Ultragenyx, as applicable, for additional
information relating to such Transition Services in a timely manner.

 

3.1.4 Transition
Services Costs. Ultragenyx will reimburse Abeona for Transition Costs in accordance with Schedule 3.1.4, including incurred
Transition Costs up to [***] percent ([***]%) of the amount included in the then-current Schedule 3.1.4. If Abeona believes that
Transition Costs are likely to exceed [***] percent ([***]%) of the amount included in the then-current Schedule 3.1.4, Abeona
will promptly revise the Transition Costs and submit it in writing, with an explanation of the variance and the reasons therefor, simultaneously
to the JTT and the Executive Officers. If the Executive Officers or their designees unanimously approve of the revised Schedule 3.1.4
then such revised Transition Costs will be deemed incorporated into the Transition Plan and if the Executive Officers or their designees
do not unanimously approve of the revised Schedule 3.1.4 then Abeona shall be relieved of providing additional Transition Services.

 

3.2 Transfer
of Licensed Know-How. Promptly following the Effective Date (but in any event within [***] days thereof), Abeona will, and will cause
its Affiliates and contractors to, transfer to Ultragenyx or its designee the Know-How forth on Schedule 3.2. In addition, Abeona
will disclose and make available to Ultragenyx additional Licensed Know-How that exists as of the Effective Date pursuant to and within
the timeframes set forth in the Transition Plan. Following the Transition Period and throughout the Term, Abeona will disclose and make
available to Ultragenyx any additional Licensed Know-How of which Abeona or Ultragenyx becomes aware and respond to any requests by Ultragenyx
for additional Licensed Know-How.

 

3.3 Manufacturing
Technology Transfer; Assignment of Inventory. Within [***] days of the Effective Date, Abeona will transfer to Ultragenyx or its
designee in an orderly manner, (a) copies of all data, information, and other Know-How, including Materials, Controlled by Abeona or
its Affiliates and (b) all data, information and other Know-How, including Materials, Controlled by any Existing Vendor or other (sub)contractor
of Abeona or its Affiliates, in each case ((a) and(b)), that are necessary or reasonably useful to enable Ultragenyx and its designees
to Manufacture each Licensed Product. Abeona hereby assigns to Ultragenyx all of Abeona’s right, title and interest in and to the
Inventory.

 

3.4 Assignment
of Existing Vendor Agreements. At any time during the Transition Period, upon Ultragenyx’s request, Abeona will: (a) assign,
or cause its Affiliates to assign, to Ultragenyx or its designee any of the Existing Vendor Agreements, if Abeona is permitted to make
such assignment under the terms of the Existing Vendor Agreement; or (b) reasonably assist Ultragenyx or its Affiliate in entering into
new agreements directly with the counterparties to any of the Existing Vendor Agreements to cover the subject matter related to the Licensed
Products, as applicable. Each such assignment under this Section 3.4 will include the assignment to Ultragenyx of any pre-paid positions
or credits in favor of Abeona or its Affiliate under the corresponding Existing Vendor Agreement.

 

    	16

     

    

 

3.5 Ongoing
Abeona Assistance. During the Term, in addition to the Transition Services, Abeona will reasonably cooperate with and provide information
and assistance to Ultragenyx or its designee, at Ultragenyx’s cost, through documentation, consultation, and face-to-face meetings,
in connection with the exercise of the licenses and rights granted to Ultragenyx, its Affiliates and Sublicensees under this Agreement,
including as useful or necessary to enable Ultragenyx or its designees, to proceed with Exploitation of the Licensed Products and to
obtain all appropriate Regulatory Approvals for the Licensed Products in an efficient and timely manner. In furtherance of the foregoing,
if requested by Ultragenyx, Abeona will provide Ultragenyx and its designees with reasonable and timely access to qualified Abeona personnel
(and personnel of its Affiliates and Third Party contractors) involved in Development or Manufacturing matters related to the Licensed
Products, to assist in transferring data, information, and other Know-How to Ultragenyx or its designee; provided, that such assistance
will not exceed [***] hours in a given Calendar Year and Abeona’s obligations under this Section 3.5 will expire on September 30,
2023.

 

3.6 Spain
Entity. Upon the written request of Ultragenyx, such request to be made (if at all) during the Transition Period, the Parties will
negotiate in good faith the sale by Abeona, and purchase by Ultragenyx, of Abeona Therapeutics Europe, S.L., without additional consideration.

 

ARTICLE
4

DEVELOPMENT,
REGULATORY, MANUFACTURE AND COMMERCIALIZATION

 

4.1 Development
Activities.

 

4.1.1 Development
Responsibilities and Compliance. Subject to the terms and conditions of this Agreement, Ultragenyx will be solely responsible for
managing and performing all activities relating to the Development of each Licensed Product, including obtaining and maintaining Regulatory
Approval in the Field and in the Territory, except for such Development activities performed by Abeona (directly, or through its Affiliates
or permitted Third Party contractors) as part of the Transition Services.

 

4.1.2 Development
Diligence. Subject to the terms and conditions of this Agreement, Ultragenyx (directly, or through its Affiliates, Sublicensees or
contractors) will use Commercially Reasonable Efforts to Develop at least one Licensed Product in the Field in the Territory. Ultragenyx
will not be deemed to be in breach of its obligations under this Section 4.1 to the extent it is prevented from or delayed in using Commercially
Reasonable Efforts to Develop a Licensed Product as a result of the acts or omissions of Abeona.

 

4.1.3 Development
Costs. Ultragenyx will have sole responsibility for (a) all External Costs and FTE Costs incurred by or on behalf of Ultragenyx related
to the Development of each Licensed Product during the Term and (b) the Prior Development Costs incurred by or on behalf of Abeona during
the period of time beginning on March 15, 2022 and ending on the Effective Date, as set forth on Schedule 4.1.3. In no event will
Ultragenyx have any responsibility for costs incurred by Abeona prior to March 15, 2022, which will be borne solely by Abeona even if
any such costs are invoiced on or after March 15, 2022. Without limiting the foregoing, Abeona’s obligations under this Section
4.1.3 include the obligation to pay any costs under the Nationwide Children’s Agreement that accrued prior to March 15, 2022 and
if Ultragenyx pays Nationwide Children’s any such costs under the Nationwide Children’s Agreement, then Abeona will promptly
reimburse Ultragenyx for the same.

 

    	17

     

    

 

4.2 Regulatory
Submissions and Approvals.

 

4.2.1 Regulatory
Responsibilities.

 

(a) During
the Transition Period, to the extent set forth in the Transition Plan, the Transition Services may include preparing and submitting Regulatory
Materials and otherwise with respect to obtaining Regulatory Approvals for the Licensed Products and in the activities in support thereof.
Abeona will perform any such Transition Services in accordance with the Transition Plan. Abeona will provide any Regulatory Materials
to be filed or submitted by Abeona with respect to any Licensed Product, including any draft correspondence or communication with Regulatory
Authorities, to Ultragenyx, and, for the avoidance of doubt, will not file or submit any Regulatory Materials (or convey any such correspondence
or communication to any Regulatory Authority) with respect to any Licensed Product without prior written approval by Ultragenyx.

 

(b) Ultragenyx
will have the sole right, and will use Commercially Reasonable Efforts, itself or with or through its Affiliates, Sublicensees, or other
Third Parties, to: (a) prepare and submit to applicable Regulatory Authorities all Regulatory Materials for the Licensed Products; and
(b) obtain and maintain all Regulatory Approval and Pricing and Reimbursement Approval for the Licensed Products at Ultragenyx’s
sole cost and expense.

 

4.2.2 Communications
with Regulatory Authorities. Except as set forth in Section 4.2.1(a), as between the Parties, Ultragenyx will have the sole right
to correspond or communicate with Regulatory Authorities regarding the Licensed Products during the Term and, upon the reasonable request
of Ultragenyx, Abeona will, at Ultragenyx’s cost, support Ultragenyx with respect to such activities. For clarity, unless required
by Applicable Law, Abeona, its Affiliates, and its permitted subcontractors will not correspond or communicate with Regulatory Authorities
regarding any Licensed Product without first obtaining Ultragenyx’s prior written consent. If Abeona, any of its Affiliates, or
any of its permitted subcontractors receives any correspondence or other communication from a Regulatory Authority regarding a Licensed
Product, then Abeona will promptly provide Ultragenyx with access to or copies of all such material written or electronic correspondence
promptly after its receipt.

 

4.2.3 Ownership
of Regulatory Approvals. Ultragenyx will own all Regulatory Materials, including all submissions and applications for Regulatory
Approvals, and Regulatory Approvals, for the Licensed Products in the Field in the Territory. Abeona hereby assigns and transfers to
Ultragenyx (or its designee), and will cause its Affiliates to assign or transfer, any and all such Regulatory Materials. Within [***]
days after the Effective Date, Abeona will provide to Ultragenyx true, accurate, and complete electronic copies, and hard copies, to
the extent they exist as of the Effective Date and are not duplicative of such electronic copies thereof (taking into consideration the
legibility of such electronic copies).

 

4.2.4 Right
of Reference to Regulatory Materials. For any Regulatory Materials Controlled by Abeona or its Affiliates that are not timely assigned
and transferred in accordance with Section 4.2.4, Abeona will and hereby does grant to Ultragenyx a “Right of Reference,”
(as defined in 21 C.F.R. § 314.3(b) as applied to an IND or BLA (or any successor rule), or similar “right of reference”
as defined in applicable regulations in the relevant jurisdiction), to, and a right to copy, access, and otherwise use, all information
and data included in any Regulatory Materials that are Controlled by Abeona or its Affiliates to the extent necessary or reasonably useful
to assist Ultragenyx in obtaining Regulatory Approval for any Licensed Product in the Field. Abeona will provide a signed statement to
this effect, if requested by Ultragenyx, in accordance with 21 C.F.R. § 314.50(g)(3) (or any successor rule or analogous Applicable
Law recognized outside of the United States).

 

4.2.5 Regulatory
Cooperation. Notwithstanding Section 3.5, Abeona will provide reasonable cooperation and support to Ultragenyx, at Ultragenyx’s
cost, in preparing and submitting Regulatory Materials and obtaining Regulatory Approvals for each Licensed Product and in the activities
in support thereof.

 

    	18

     

    

 

4.3 Manufacturing
Activities. Ultragenyx, its Affiliates, its or their Sublicensees or subcontractors will be solely responsible, at Ultragenyx’s
sole cost and expense, for Manufacturing and supplying requirements for the Development and Commercialization of the Licensed Products
in the Territory, except for such Manufacturing activities performed by Abeona (directly, or through its Affiliates or permitted Third
Party contractors) as part of the Transition Services.

 

4.4 Commercialization.
Upon receipt of the Regulatory Approval for a Licensed Product in the Field in a given country in the Territory, Ultragenyx (directly,
or through its Affiliates, its or their Sublicensees or subcontractors) will use Commercially Reasonable Efforts to Commercialize such
Licensed Product in the Field in such country in the Territory. As between the Parties, Ultragenyx will be solely responsible for and
will have sole discretion with respect to, Commercializing each of the Licensed Products in the Field in the Territory, including development
and implementation of any promotional or branding strategy and materials, handling all returns, recalls, order processing, booking sales,
invoicing and collections, inventory and receivables, and price matters.

 

4.5 Development
and Commercialization Reporting. Beginning on March 31 of the Calendar Year following the end of the Transition Period, and on each
such anniversary thereafter prior to the date on which the first report is due under Section 6.5, Ultragenyx will submit to Abeona a
written report summarizing Ultragenyx’s material Development and Commercialization activities with respect to the Licensed Products
pursuant to this Agreement since the date of Ultragenyx’s delivery of the prior report, and, with respect to the first of such
reports, since the Effective Date.

 

ARTICLE
5

JOINT
TRANSITION TEAM

 

5.1 Joint
Transition Team.

 

5.1.1 Formation;
Purposes and Principles. Within [***] days after the Effective Date, Abeona and Ultragenyx will form a core team (the “Joint
Transition Team” or “JTT”) to facilitate information sharing between the Parties with respect to the Development
of the Licensed Products. The Joint Transition Team will be a discussion body only and will not have decision-making power.

 

5.1.2 Specific
Responsibilities. In addition to its overall responsibility to facilitate information sharing between the Parties with respect to
the Development activities under this Agreement, the Joint Transition Team will:

 

(a) review
and discuss proposed amendments or revisions to the Transition Plan or Transition Costs(for clarity, Ultragenyx will have the final decision
making authority to approve the Transition Plan as described in Section 3.1.2; provided that (i) any amendment or revision to add additional
material obligations that are not set forth in the Transition Plan will require Abeona’s consent, (ii) any reduction in the Transition
Costs without a corresponding decrease in activities under the Transition Plan will require Abeona’s consent, and (iii) any proposed
increase in the Transition Costs will be subject to Section 3.1.4);

 

(b) exchange
information with respect to the Transition Services, and review and discuss Abeona’s activities and progress under the Transition
Plan;

 

(c) discuss
and attempt to resolve any issues related to the Transition Plan;

 

(d) discuss
the transfer of Licensed Know-How and serve as a forum for Abeona to answer questions with respect to such Licensed Know-How;

 

    	19

     

    

 

(e) exchange
information with respect to the Development of Licensed Products;

 

(f) exchange
information with respect to Abeona’s ongoing support obligations under Section 3.5; and

 

(g) perform
such other functions as are assigned to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent
agreed to in writing by the Parties.

 

5.1.3 Membership.
The Joint Transition Team will be composed of representatives of each Party; provided that neither Party may appoint more than [***]
representatives to the Joint Transition Team. In accordance with the foregoing, each Party will appoint members to the Joint Transition
Team. Each individual appointed by a Party as a representative to the Joint Transition Team will be an employee or consultant (provided
that any such consultant is under obligations of confidentiality and non-use with respect to the Confidential Information of each Party
in keeping with Section 8.1) of such Party with sufficient seniority within the applicable Party to provide meaningful input and make
decisions arising within the scope of the Joint Transition Team’s responsibilities, and have knowledge and expertise in the Development
of products similar to the Licensed Products under this Agreement. Each Party may replace any of its Joint Transition Team representatives
at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party. The Joint Transition
Team will be co-chaired by one designated representative of each Party. Each Joint Transition Team representative and the Alliance Manager
(as defined in Section 5.2) will be subject to confidentiality obligations no less stringent than those in ARTICLE 8.

 

5.1.4 Meetings.
The Joint Transition Team will hold meetings at least [***] per [***] during the Transition Period, with the option to hold additional
meetings on an ad hoc basis. Prior to any meeting of the Joint Transition Team an agenda for such meeting will be prepared and circulated
by the Alliance Managers. Either Party may also call a special meeting of the Joint Transition Team by providing reasonable prior written
notice (e-mail to the other Party’s Alliance Manager will suffice) to the other Party. The Joint Transition Team may meet in person
or by audio or video conference as its representatives may mutually agree. Other representatives of the Parties, their Affiliates and
Third Parties involved in the Development of Licensed Products may be invited by the members of the Joint Transition Team to attend meetings
as observers or to facilitate discussions outside of meetings; provided, however, that such representatives are subject to confidentiality
obligations no less stringent than those set forth in ARTICLE 8. The minutes of each Joint Transition Team meeting will be prepared and
circulated in accordance with the procedures established by the Joint Transition Team. Each Party will be responsible for its costs to
attend each meeting of the Joint Transition Team.

 

5.1.5 Sub-teams.
From time to time, the Joint Transition Team may establish sub-teams, as it deems necessary or advisable to further the purposes of this
Agreement, including any responsibilities assigned to the Joint Transition Team under this Agreement; provided, however, that no sub-team
will have any power to amend, modify or waive compliance with this Agreement. Each sub-team will consist of [***] number of representatives
of each Party (unless otherwise agreed by the Parties) and meet with such frequency as the Joint Transition Team determines is appropriate
from time to time. The purpose, scope and procedures of any such sub-team will be mutually agreed by the Parties.

 

5.1.6 Disbanding
of Joint Transition Team. Unless otherwise agreed by the Parties, the Joint Transition Team will have no further responsibilities
and will automatically disband upon expiration of the Transition Period.

 

    	20

     

    

 

5.2 Alliance
Managers. Promptly after the Effective Date, each Party will appoint an individual to act as alliance manager for such Party (each,
an “Alliance Manager”). The Alliance Managers will be the primary point of contact for the Parties regarding communications
contemplated by this Agreement, whether formal reporting obligations or otherwise, including after disbanding of the Joint Transition
Team. The Alliance Managers will also be responsible for assisting the Joint Transition Team in performing its responsibilities such
as scheduling meetings, circulating agendas as necessary and preparing and finalizing the minutes from meetings of the Joint Transition
Team. Each Party may replace its Alliance Manager, in its sole discretion, from time to time, upon notification to the other Party, which
notice may be given by e-mail, sent to the other Party’s Alliance Manager.

 

ARTICLE
6

FINANCIAL
PROVISIONS

 

6.1 Prior
Development Costs. Ultragenyx will pay the Prior Development Costs in accordance with Section 6.7.

 

6.2 Milestone
Payments.

 

6.2.1 Commercial
Milestones. During the Term, Ultragenyx will pay Abeona the milestone payments set forth in this Section 6.2.1 (each, a “Milestone
Payment”) upon the achievement of the relevant milestone event with respect to the Licensed Products (each, a “Milestone
Event”), subject to the limitations set forth in this Section 6.2.1. Each of the Milestone Payments is payable only upon the
first achievement of such Milestone Event and none of the Milestone Payments will be payable more than once and no amounts will be due
for subsequent or repeated achievements of such Milestone Event. For clarity, the Milestone Payments will be additive such that if both
Milestone Events set forth below are achieved in the same Calendar Year, Ultragenyx will pay to Abeona a payment of Thirty Million Dollars
($30,000,000), and the maximum aggregate amount of Milestone Payments payable by Ultragenyx pursuant to this Section 6.2.1 is Thirty
Million Dollars ($30,000,000).

 

	Milestone
    Event	 	Milestone
    Payment (in Dollars)	 
	1. Aggregate annual Net
    Sales of all Licensed Products in the Territory in a Calendar Year are greater than [***] Dollars ($[***])	 	$	[***]	 
	2.
    Aggregate annual Net Sales of all Licensed Products in the Territory in a Calendar Year are greater than [***] Dollars ($[***])	 	$	[***]	 
	Total	 	$	30,000,000	 

 

6.2.2 Notice;
Payment. Each Milestone Payment will be deemed earned upon achievement of the corresponding Milestone Event, and Ultragenyx will
provide Abeona with written notice of the achievement of each of the Milestone Events set forth in Section 6.2.1 within [***] days after
the end of the Calendar Year in which such Milestone Event is first achieved. Ultragenyx will pay to Abeona the applicable Milestone
Payment within [***] days of receipt of Abeona’s invoice therefor, such invoice to be issued after receipt of notice from Ultragenyx
under this Section 6.2.2.

 

    	21

     

    

 

6.3 Royalties.

 

6.3.1 Royalty
Rate. Subject to the terms and conditions of this Agreement, and in partial consideration for the rights granted to Ultragenyx under
this Agreement, during the Royalty Term, Ultragenyx will pay to Abeona non-refundable, non-creditable royalties (except in the case of
an overpayment as set forth in Section 6.9.2) at the graduated royalty rates specified in the applicable table set forth in either (a)
or (b) below with respect to the aggregate annual worldwide Net Sales of all Licensed Products sold by a Selling Party in the Territory
in a given Calendar Year:

 

(a) Royalties
on Licensed Products if FDA approval of a BLA for the first Licensed Product in the Field is received by Ultragenyx on or before [***]:

 

	Aggregate Annual Worldwide Net Sales of all Licensed
    Products in a Calendar Year	 	Royalty Rate
	Portion of aggregate annual worldwide Net Sales up
    to and including [***] Dollars ($[***])	 	[***] percent ([***]%)
	Portion of aggregate annual worldwide Net Sales greater
    than [***] Dollars ($[***]) up to and including [***] Dollars ($[***])	 	[***] percent ([***]%)
	Portion of aggregate annual worldwide Net Sales greater
    than [***] Dollars ($[***])	 	Ten percent (10%)

 

(b) Royalties
on Licensed Products if FDA approval of a BLA for the first Licensed Product in the Field is not received by Ultragenyx on or before
[***]:

 

	Aggregate Annual Worldwide Net Sales of all Licensed
    Products in a Calendar Year	 	Royalty Rate
	Portion of aggregate annual worldwide Net Sales up
    to and including [***] Dollars ($[***])	 	[***] percent ([***]%)
	Portion of aggregate annual worldwide Net Sales greater
    than [***] Dollars ($[***]) up to and including [***] Dollars ($[***])	 	[***] percent ([***]%)
	Portion of aggregate annual worldwide Net Sales greater
    than [***] Dollars ($[***])	 	[***] percent ([***]%)

 

6.3.2 Royalty
Term. Royalties will be due under this Section 6.3 with respect to a given Licensed Product only during the Royalty Term.

 

6.3.3 Only
One Royalty. The obligation to pay royalties will be imposed only once with respect to the same unit of a Licensed Product even if
the manufacture, use or sale of such Licensed Product is covered by more than one of the Licensed Patents.

 

6.4 Royalty
Payment Reductions. The royalties payable under Section 6.2.2 will be subject to the following:

 

6.4.1 Third
Party Licenses. In the event that Ultragenyx identifies any Patent or Know-How Controlled by a Third Party in a particular country
or other jurisdiction that, absent a license or agreement with such Third Party, would be infringed by Exploiting a Licensed Product
in the Field in the Territory (“Blocking IP”), Ultragenyx or any of its Affiliates will have the right, but not the
obligation, to enter into an agreement with a Third Party to acquire or obtain a license, covenant not to sue or other similar right
to any Blocking IP (such agreement, a “Third Party License”). If Ultragenyx or any of its Affiliates enters into a
Third Party License, Ultragenyx will be entitled to deduct from payments due under Section 6.3 [***] percent ([***]%) of all upfront
payments, milestone payments, royalties, fees or any other amounts or consideration paid to such Third Party in respect of such Third
Party License to the extent related to the Licensed Products, including the Exploitation thereof; provided that (a) such offset will
not decrease any particular payment due under Section 6.3 by more than [***] percent ([***]%); and (b) any such deductions not fully
taken as a result of the application of the foregoing clause (a) may be carried forward by Ultragenyx to reduce subsequent amounts due
under Section 6.3 until all such deductions are fully taken. Abeona hereby covenants that it will not, and will cause its Affiliates
not to, negotiate or enter into any Third Party License specific to the Exploitation of a Licensed Product or specific to the Exploitation
of a product in the Field.

 

    	22

     

    

 

6.4.2 Lack
of Patent Protection and Regulatory Exclusivity. Subject to 6.4.4, the royalties payable to Abeona with respect to Net Sales of Licensed
Products will be reduced, on a Licensed Product–by–Licensed Product and country-by-country basis, to [***] percent ([***]%)
of the amounts otherwise payable pursuant to Section 6.3.1 during any portion of the Royalty Term upon the later of (a) expiration of
the last-to-expire Valid Claim Covering the applicable Licensed Product in such country, or at the time of First Commercial Sale in such
country if no such Valid Claim exists in such country at such time, and (b) expiration of Regulatory Exclusivity for such Licensed Product
in such country, or at the time of First Commercial Sale in such country if no such Regulatory Exclusivity exists in such country at
such time.

 

6.4.3 Biosimilar
Competition. If, on a Licensed Product-by-Licensed Product and country-by-country basis, at least one Biosimilar Product is commercially
available with respect to such Licensed Product in such country and the combined market share for all such Biosimilar Products is (i)
greater than [***] percent ([***]%) but no greater than [***] percent ([***]%) of the total market (i.e., the total number of units for
such Biosimilar Product(s) and Licensed Product), then the royalties on Net Sales of such Licensed Product in such country will be reduced
by [***] percent ([***]%) as of the Calendar Quarter in which such Biosimilar Product(s) obtain such combined market share, or (ii) greater
than [***] percent ([***]%) of the total market (i.e., the total number of units for such Biosimilar Product(s) and Licensed Product),
then the royalties on Net Sales of such Licensed Product in such country will be reduced by [***] percent ([***]%) as of the Calendar
Quarter in which such Biosimilar Product(s) maintain such combined market share. Unit volume sales will be identified and calculated
based on relevant information published by IQVIA, any successor to IQVIA, or any other similar industry-standard Third Party source used
by Ultragenyx.

 

6.4.4 Cumulative
Deductions. Notwithstanding the foregoing, in no event will the deductions set forth in Section 6.4.1 through Section 6.4.3 reduce
any royalty payment that is payable to Abeona as specified in Section 6.3.1 by more than [***] percent ([***]%).

 

6.5 Royalty
Payments and Reports. Within [***] days after the end of each Calendar Quarter, commencing with the Calendar Quarter during which
the First Commercial Sale of a Licensed Product is made anywhere in the Territory, Ultragenyx will provide to Abeona a report setting
forth on a Licensed Product–by–Licensed Product and country-by-country basis (a) the Net Sales; and (b) the calculation of
the royalties payable under this Agreement on account of those Net Sales. Each royalty report along with the royalties shown to have
accrued on that report are due and payable to Abeona within [***] days following the end of such Calendar Quarter. All payments due under
this Section 6.5 will be made by bank wire transfer or ACH payment in immediately available funds to an account designated by Abeona.

 

6.6 Invoicing
for Additional Amounts. With respect to any amounts owed under this Agreement by one Party to the other Party for which no other
invoicing or payment procedure is specified elsewhere in this Agreement, within [***] days after the end of each Calendar Quarter, the
applicable Party will provide an invoice, together with reasonable supporting documentation, to the other Party for such amounts owed
that were incurred or accrued during such Calendar Quarter. The owing Party will pay any undisputed amounts within [***] days of receipt
of the invoice, and any disputed amounts owed by the owing Party will be paid within [***] days of resolution of the Dispute.

 

    	23

     

    

 

6.7 Reimbursement
of Prior Development Costs and Transition Costs. Ultragenyx will reimburse Abeona for the Prior Development Costs and Transition
Costs actually incurred by Abeona or its Affiliates for the Transition Services in accordance with the Transition Plan (subject to Section
3.1.4). Abeona will provide an invoice for the Prior Development Costs and Transition Costs each month in arrears, and any payments to
be made to Abeona by Ultragenyx pursuant to this Section 6.7 will be made within [***] days of receipt of invoices submitted by Abeona
to Ultragenyx. Each such invoice will be accompanied by reasonable supporting documentation. Payment for Transition Costs will not exceed
the amounts calculated in accordance with Section 3.1.4.

 

6.8 Costs.
Except as otherwise set forth herein, each Party will bear its own costs incurred under this Agreement.

 

6.9 Financial
Audits.

 

6.9.1 Record
Keeping. Ultragenyx and its Affiliates will, and will cause their respective Sublicensees to, keep complete, true and accurate books
and records in accordance with its Accounting Standards of the items underlying (a) Net Sales, and (b) royalty payments under this Agreement.
Ultragenyx and its Affiliates will, and will cause their respective Sublicensees to keep, such books and records for at least [***] years
following the Calendar Quarter to which they pertain. Abeona will have the right annually, at its own expense, to have an internationally-recognized
independent, certified public accountant, selected by Abeona and reasonably acceptable to Ultragenyx (the “Auditor”),
review any such records of Ultragenyx in the location(s) where such records are customarily maintained by Ultragenyx upon at least [***]
days’ prior written notice, during regular business hours and under obligations of confidentiality, except to the extent necessary
to enforce Abeona’s rights under this Agreement or if disclosure is required by Applicable Law, for the sole purpose of verifying
the basis and accuracy of payments made under this Agreement and the content of the reports described in Section 6.5, within the prior
[***] Calendar Year period after receipt of such report. The Auditor will have the right to disclose to Abeona its conclusions regarding
any payment owed under this Agreement. The records for any Calendar Year may be audited no more than once with respect to records covering
any specific period of time.

 

6.9.2 Audit
Report. The report prepared by the Auditor, a copy of which will be sent or otherwise provided to each Party by such Auditor at the
same time before such report is considered final, will contain the conclusions of such Auditor regarding the audit and will specify that
the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment, and the specific details
regarding any discrepancies. No other information will be provided to Abeona without the prior consent of Ultragenyx unless disclosure
is required by Applicable Laws and if so determined by Abeona in consultation with Ultragenyx, it will, if permitted, give Ultragenyx
prior notice thereof to the extent possible for Ultragenyx to seek a protective order against or limiting such disclosure. If such report
shows any underpayment, then Ultragenyx will remit to Abeona, within [***] days after receipt of such report, (a) the amount of such
underpayment and (b) if such underpayment exceeds [***] percent ([***]%) of the total amount owed for the period then being audited,
the actual auditor costs incurred by Abeona in conducting such review. For the avoidance of doubt, payment of the underpayment will be
considered a late payment, subject to Section 6.13. If such report shows any overpayment, then at Ultragenyx’s election, either
Ultragenyx will deduct the overpaid amount for application against future payments owed to Abeona or Abeona will reimburse Ultragenyx
the amount of such overpayment. The Parties mutually agree that all information subject to review under this Section 6.9 is Confidential
Information of Ultragenyx, and that Abeona will cause the Auditor to retain all such information in confidence in accordance with confidentiality
and non-use obligations no less stringent than those contained in ARTICLE 8. Notwithstanding the foregoing, if Ultragenyx challenges
the results of the audit in good faith, Ultragenyx will be entitled at its own cost and expense to obtain a second independent certified
public accountant to confirm the accuracy of the first audit. If the results of such confirmatory audit are within [***] percent ([***]%)
of the results of the first audit, any amounts owed or overpaid by Ultragenyx will be paid or refunded in accordance with the procedures
above. If the results of such confirmatory audit are not substantially similar to the results of the first audit, each Party shall cause
its respective auditors to identify the discrepancy and to agree on a final amount owed or overpaid (as the case may be) by Ultragenyx
that shall be final and binding on the Parties.

 

    	24

     

    

 

6.10 Withholding
Taxes. Ultragenyx may withhold from payments due to Abeona amounts for payment of any withholding tax that is required by Applicable
Law to be paid to any taxing authority with respect to such payments. Ultragenyx will provide Abeona all relevant documents and correspondence,
and will also provide to Abeona any other cooperation or assistance on a reasonable basis as may be necessary to enable Abeona to claim
exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Ultragenyx will
give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions
under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Ultragenyx making
payments from a single source in the U.S., where possible.

 

6.11 Blocked
Payments. In the event that, by reason of Applicable Law in any country, it becomes impossible or illegal for Ultragenyx to transfer,
or have transferred on its behalf, payments owed Abeona hereunder, Ultragenyx will promptly notify Abeona of the conditions preventing
such transfer and such payments will be deposited in local currency in the relevant country to the credit of Abeona in a recognized banking
institution designated by Abeona or, if none is designated by Abeona within a period of [***] days, in a recognized banking institution
selected by Ultragenyx, as the case may be, and identified in a written notice given to Abeona.

 

6.12 Manner
of Payments; Currency. All payments to be made by Ultragenyx hereunder will be made in Dollars by wire transfer to such bank account
as Abeona may designate. For any currency conversion from the currency of one country in which the Licensed Products are sold into U.S.
Dollars (or another currency if applicable) required in determining the amount of Net Sales or any royalties or revenue share due hereunder,
such conversion will be equal to the average exchange rate, over the applicable Calendar Quarter, calculated at the conversion rate as
reported by OANDA (www.oanda.com), or an equivalent or similar resource as agreed by the Parties, on the last Business Day of the Calendar
Quarter in which the applicable Net Sales were made.

 

6.13 Late
Payments. Without limiting any other rights or remedies available to Abeona hereunder, any undisputed late payment or portion thereof
by Ultragenyx will bear interest, to the extent permitted by Applicable Law, at an annual rate of [***] percent ([***]%) above the applicable
daily rate published in the Wall Street Journal (or any other qualified source that is acceptable to both Parties) on the date payment
was due or the highest rate permitted by Applicable Law (whichever is lower), computed from the date such payment was due until the date
Ultragenyx makes the payment. Where the late payment is caused by Abeona, including for reasons such as failure to communicate in a timely
manner changes to bank details, or failure to respond to communications from Ultragenyx regarding the interpretation or dispute of the
terms of such payment, then no interest will be payable by Ultragenyx.

 

ARTICLE
7

INTELLECTUAL
PROPERTY OWNERSHIP,

PROTECTION
AND RELATED MATTERS

 

7.1 Ownership.

 

7.1.1 Pre-Existing
IP. Subject only to the rights expressly granted to the other Party under this Agreement, each Party will retain all rights, title,
and interests in and to all Patents, Know-How and other intellectual property rights that are owned, licensed, or sublicensed by such
Party prior to or independent of this Agreement.

 

    	25

     

    

 

7.1.2 Sole
Inventions. Except as set forth in this Section 7.1.2, as between the Parties, each Party will own all inventions and Know-How that
are conceived, discovered, developed or otherwise made, as necessary to establish authorship (in case of publication and other copyrightable
work), inventorship (in case of inventions, whether patentable or not) or ownership under Applicable Law, solely by or on behalf of such
Party (or its Affiliates, its or their subcontractors or sublicensees (including Sublicensees) or its or their respective directors,
officers, employees or agents) in the course of performing such Party’s activities or exercising such Party’s rights under
this Agreement, and any and all Patents and other intellectual property rights thereto (collectively, “Sole Inventions”).
As between the Parties, (a) Ultragenyx will own all inventions and Know-How that are conceived, discovered, developed or otherwise made
(i) solely by or on behalf of Ultragenyx or (ii) solely by or on behalf of Abeona or jointly by or on behalf of each Party in the performance
of the Transition Services that, in the case of (ii), constitute an improvement or modification of a Licensed Product or improvement
or modification to any Know-How or Patents that relate to a product in the Field that are Controlled by Ultragenyx (collectively, ((i)
and (ii)), “Ultragenyx Sole Inventions”), and (b) Abeona will own all inventions and Know-How that are conceived,
discovered, developed or otherwise made solely by or on behalf of Abeona (i) outside of the performance of the Transition Services or
(ii) solely by or on behalf of Abeona in the performance of the Transition Services that do not constitute an Ultragenyx Sole Invention
as described in clause (a)(ii) of the definition of Ultragenyx Sole Inventions (“Abeona Sole Inventions”). All Patents
claiming patentable Ultragenyx Sole Inventions will be referred to herein as “Ultragenyx Patents”. All Patents claiming
patentable Abeona Sole Inventions described in clause (ii) of the definition of Abeona Sole Inventions are hereby deemed Licensed Patents
and all Know-How that is an Abeona Sole Invention described in such clause (ii) is hereby deemed Licensed Know-How. Abeona hereby assigns,
and agrees to assign, to Ultragenyx all right, title and interest in and to the Ultragenyx Sole Inventions that are described in clause
(a)(ii) of the definition of Ultragenyx Sole Inventions.

 

7.1.3 Joint
Inventions. As between the Parties, except for any Ultragenyx Sole Inventions described in clause (a)(ii) of Section 7.1.2, each
Party will own an equal, undivided interest in all inventions and Know-How that are conceived, discovered, developed or otherwise made,
as necessary to establish authorship (in case of publication and other copyrightable work), inventorship (in case of inventions, whether
patentable or not) or ownership under Applicable Law, jointly by or on behalf of each Party (or their respective Affiliates, subcontractors
or sublicensees (including Sublicensees) or its or their respective directors, officers, employees or agents) in the course of performing
activities or exercising rights under this Agreement during the Transition Period (collectively, “Joint Inventions”),
and any and all Joint Patents and other intellectual property rights thereto. Each Party will have full rights to license, assign and
exploit such Party’s interest in such Joint Inventions (and any Joint Patents arising therefrom) anywhere in the world, without
any requirement of gaining the consent of, or accounting to, the other Party, subject to the licenses granted herein and subject to any
other intellectual property held by such other Party. Each Party will promptly disclose to the other all Joint Inventions, in each case,
including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates’ subcontractors
or sublicensees (including Sublicensees’) or its or their directors, officers, employees or agents, describing such Joint Inventions.

 

7.1.4 Assignment
Obligation. Each Party will cause all employees of such Party who perform activities for such Party under this Agreement to be under
an obligation to assign their rights prior to performing any such activities, in any Patents and Know-How, whether or not patentable,
resulting therefrom to such Party to effectuate the terms and conditions set forth in this Section 7.1. With respect to any activities
of a Party under this Agreement that are subcontracted to a Person that is not an employee, the Party retaining such subcontractor will
include in the applicable subcontract an assignment to such Party of all rights in Patents and Know-How made by such subcontractor resulting
from such activities, and in any event will include in the applicable subcontract a license to such Party that is fully sublicensable
to the other Party under this Agreement and comports with the scope of the licenses granted hereunder, of any Patents and Know-How made
by such subcontractor resulting from such activities.

 

    	26

     

    

 

7.1.5 Inventorship.
Inventorship for inventions made during the course of the performance of this Agreement will be determined in accordance with United
States patent laws for determining inventorship.

 

7.2 Prosecution
and Maintenance of Patents.

 

7.2.1 Prosecution
of Licensed Patents. As between the Parties, Abeona will have the sole right, but not the obligation, to Prosecute the Licensed Patents
in the Field in the Territory at Abeona’s sole cost and expense through patent counsel or agents of its choice. In no event will
Ultragenyx, itself or in coordination with an Affiliate or Third Party, (a) Prosecute any Licensed Patent or (b) have step-in rights
with respect to the Prosecution of any of the Licensed Patents.

 

7.2.2 Cooperation
in Prosecution. Neither Ultragenyx nor its Affiliates will have any obligation to cooperate with Abeona with respect to the Prosecution
of Licensed Patents pursuant to this Section 7.2.

 

7.2.3 Prosecution
of Ultragenyx Patents. Ultragenyx will control and be responsible, at its own expense, for the Prosecution of all Ultragenyx Patents.

 

7.2.4 Patent
Extensions; Data Exclusivity and Purple Book and Patent Register Listings; Biosimilar Applications.

 

(a) Patent
Term Extension. If elections with respect to obtaining patent term extension or supplemental protection certificates or their equivalents
in any country with respect to any Licensed Product become available, then, as between the Parties, Ultragenyx will have the sole right
to determine which Joint Patent, if any, to extend. Ultragenyx shall have no right to extend the term of a Licensed Patent without Abeona’s
express written consent.

 

(b) Purple
Book and Patent Register Listings. Ultragenyx has the sole discretion to determine whether to list or de-list any Licensed Patents
or Joint Patents, if any, with the applicable Regulatory Authorities for any Licensed Product, including the FDA’s Purple Book
and all other so-called “Patent Register” listings required by certain Governmental Authorities, and all similar listings
in any other relevant countries. To the extent that Ultragenyx elects to list a Licensed Patent or Joint Patent in the Purple Book or
any foreign equivalents with respect to a Licensed Product, Ultragenyx will have the sole right to make all applicable filings with Regulatory
Authorities in the Territory with respect to such Licensed Patent or Joint Patent. Abeona shall cooperate with Ultragenyx’s reasonable
requests in connection therewith.

 

(c) Biosimilar
Applications. If either Party receives a copy of an application submitted to the FDA under subsection (k) of Section 351 of the PHSA
or any analogous application submitted to any Regulatory Authority in a country outside the United States (a “Biosimilar Application”)
naming a Licensed Product as a reference product or otherwise becomes aware that such a Biosimilar Application has been filed (including
by the receipt of information disclosed pursuant to Section 351(l)(2) of the PHSA, or in an instance described in Section 351(l)(9)(C)
of the PHSA), such Party will, within [***] Business Days, notify the other Party so that the other Party may seek permission to view
the application and related confidential information from the filer of such Biosimilar Application under Section 351(l)(1)(B)(iii) of
the PHSA. Ultragenyx will have the first right to (i) designate pursuant to Section 351(l)(1)(B)(ii) of the PHSA the outside counsel
and in-house counsel who will receive confidential access to the Biosimilar Application, (ii) (A) list any Licensed Patents, and any
other Patents, as required pursuant to Section 351(l)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA, (B) respond
to any communications with respect to such lists from the filer of the Biosimilar Application, and (C) negotiate with the filer of the
Biosimilar Application as to whether to utilize a different mechanism for information exchange than that specified in Section 351(l)
of the PHSA; and (iii) identify Licensed Patents and any other Patents, and to respond to communications under any equivalent or similar
listing in any other jurisdiction in the Territory. If Ultragenyx does not defend a given Patent within the Licensed Patents or Joint
Patents under this Section 7.2.4(c) within [***] days (or such shorter period of time before the time limit, if any, set forth in the
Applicable Law in the United States or any other country in the Territory to not waive any statutory rights), or elects not to continue
any such defense (in which case it will promptly provide notice thereof to Abeona), then Abeona will have the right, but not the obligation,
at its sole discretion and expense, to defend any such Patent.

 

    	27

     

    

 

7.3 Enforcement
of Third Party Infringement.

 

7.3.1 Notice.
Each Party will promptly notify the other in writing of any (a) apparent, threatened or actual infringement by a Third Party of any Licensed
Patent or Joint Patent, or (b) unauthorized use or misappropriation of any Licensed Know-How by a Third Party of which it becomes aware,
and, in each case, will provide the other Party with all evidence in such Party’s possession or control supporting such infringement
or unauthorized use or misappropriation (each, an “Infringement”).

 

7.3.2 Ultragenyx
Sole Right. As between the Parties, Ultragenyx will have the sole right, but not the obligation, using counsel of its choosing and
at its sole expense, to institute any Action alleging Infringement of the Licensed Patents or Joint Patents by a Third Party performing
the manufacture, use, marketing or sale of a product falling within the scope of the exclusive license granted to Ultragenyx in Section
2.1 (any such Action, an “Infringement Action”). Ultragenyx will notify and keep Abeona reasonably apprised in writing
of any such Infringement Action and will consider Abeona’s reasonable interests and requests regarding such Infringement Action.
If Abeona is joined as a party to any Infringement Action either voluntarily or by an order of the court, Abeona shall have the right
to select its own counsel at its sole expense.

 

7.3.3 Cooperation.
In any Infringement Action brought under the Licensed Patents or Joint Patents pursuant to Section 7.3.2, Abeona will, and will cause
its Affiliates to, reasonably cooperate with Ultragenyx, in good faith, and will join such suit as a party, if requested by Ultragenyx.
Furthermore, Ultragenyx will consider in good faith all reasonable and timely comments from Abeona on any proposed arguments asserted
or to be asserted in litigation related to the enforcement or defense of any such Patents. Ultragenyx will have the right to settle any
patent infringement litigation with respect to any Licensed Patent under this Section 7.3; provided that, if such settlement will diminish
the rights or interests of Abeona, then Ultragenyx will consider in good faith reasonable and timely comments from Abeona.

 

7.3.4 Expenses.
Subject to Section 7.3.5, Ultragenyx will be solely responsible for all expenses arising from a suit or Action against an Infringement
Action, including Abeona’s internal expenses (e.g., FTEs) incurred as a result of Abeona’s cooperation with the enforcement
of an Infringement Action as provided in this Section 7.3. Abeona will be entitled, at Abeona’s option, to separate representation
in such matter by counsel of its own choice and at its own expense, or by Ultragenyx’s counsel at Ultragenyx’s expense, but
Abeona will at all times cooperate fully with Ultragenyx.

 

7.3.5 Allocation
of Recoveries. Any settlements, damages or monetary awards recovered by Ultragenyx pursuant to any Infringement Action with respect
to the Licensed Patents or Joint Patents will, after reimbursing the Parties for their reasonable expenses in making such recovery (which
amounts will be allocated pro rata if insufficient to cover the totality of such expenses) be retained by Ultragenyx; provided, however,
that to the extent that any award or settlement (whether by judgment or otherwise) with respect to a Licensed Patent or Joint Patent
is attributable to loss of sales or profits with respect to a Licensed Product, such amount will be paid to or retained by Ultragenyx
and treated as “Net Sales” in the Calendar Quarter in which the money is actually received and any royalties pursuant to
Section 6.3 will be payable by Ultragenyx to Abeona with respect thereto.

 

    	28

     

    

 

7.4 Defense
Against Third Party Infringement Claims.

 

7.4.1 Ultragenyx
Right to Control Defense. Each Party will promptly notify the other Party if a Third Party brings any Action alleging patent infringement
by Ultragenyx or Abeona or any of their respective Affiliates or sublicensees with respect to the Exploitation of any Licensed Product
(any such Action, an “Infringement Claim”) in the Territory. Ultragenyx will have the first right, but not the obligation,
to control the defense and response to any such Infringement Claim in the Territory, at Ultragenyx’s sole cost and expense, and
Abeona will have the right, at its own expense, to be represented in any such Infringement Claim in the Territory by counsel of its own
choice. Upon the request of Ultragenyx, Abeona will reasonably cooperate with Ultragenyx in the reasonable defense of such Infringement
Claim. Abeona will have the right to consult with Ultragenyx concerning any Infringement Claim and to participate in and be represented
by independent counsel in any associated litigation. Ultragenyx will (a) consult with Abeona as to the strategy for the prosecution of
such defense, (b) consider in good faith any comments from Abeona with respect thereto and (c) keep Abeona reasonably informed of any
material steps taken and provide copies of all material documents filed, in connection with such defense. Ultragenyx will have the right
to settle such Infringement Claim on terms deemed reasonably appropriate by it; provided, that, if such settlement will diminish the
rights or interests of Abeona, then Ultragenyx will consider in good faith reasonable and timely comments from Abeona.

 

7.4.2 Step-In
Right. If Ultragenyx elects not to defend or control the defense of any Infringement Claim, or otherwise fails to initiate and maintain
the defense of any such Infringement Claim, then Abeona may conduct and control the defense of such Infringement Claim at its own expense
subject to the terms of Section 7.4.1 (mutatis mutandis, including Abeona in the place of Ultragenyx).

 

7.5 Common
Interest. All information exchanged between the Parties regarding the Prosecution of Licensed Patents or Joint Patents under this
ARTICLE 7 will be deemed Confidential Information of the disclosing Party. The Parties agree and acknowledge that they have not waived,
and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Licensed Patents or the Joint Patents under
this ARTICLE 7, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to
the contrary contained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party
to the other Party under this ARTICLE 7 is protected by attorney-client privilege or any other applicable legal privilege or immunity,
such Party will not be required to disclose such information, and the Parties will in good faith cooperate to agree upon a procedure
(including entering into a specific common interest agreement, disclosing such information on a “for counsel’s eyes only”
basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

 

ARTICLE
8

CONFIDENTIALITY
AND PUBLICITY

 

8.1 Confidential
Information.

 

8.1.1 Confidentiality
Obligation. During the Term and for a period of [***] years (and indefinitely with respect to any trade secretes) after any termination
or expiration of this Agreement, each Party agrees to, and will cause its Affiliates, its and their sublicensees and subcontractors to,
keep in confidence and not to disclose to any Third Party, or use for any purpose, except to exercise its rights or perform its obligations
under this Agreement, any Confidential Information of the other Party, without the prior written consent of such disclosing Party. The
existence and terms of this Agreement are the Confidential Information of each Party, with each Party treated as the receiving Party.

 

    	29

     

    

 

8.1.2 Permitted
Disclosures. Each Party agrees that it and its Affiliates will provide or permit access to the other Party’s Confidential Information
only to the receiving Party’s employees, consultants, subcontractors, advisors and sublicensees, and to the employees, consultants,
subcontractors, advisors and sublicensees of the receiving Party’s Affiliates in each case who need to know to exercise rights
or satisfy obligations under this Agreement; provided that such recipients are subject to obligations of confidentiality and non-use
with respect to such Confidential Information no less stringent than the obligations of confidentiality and non-use of the receiving
Party pursuant to this Section 8.1 (but of duration customary in confidentiality agreements entered into for a similar purpose). Each
Party will remain responsible for any failure by its Affiliates and its and their sublicensees, and its and its Affiliates’ respective
employees, consultants, subcontractors and advisors, to treat such Confidential Information as required under this Section 8.1 as if
such Affiliates, employees, consultants, subcontractors, advisors and sublicensees were parties directly bound to the requirements of
this Section 8.1.

 

8.1.3 Confidentiality
Limitation. Notwithstanding anything to the contrary herein, each Party may use and disclose the other Party’s Confidential
Information as follows: (i) to its Affiliates, bona fide potential or actual collaborators, licensors, sublicensees, or strategic
partners and to employees, directors, agents, consultants, and advisers of such Third Parties, financial advisors, attorneys and accountants,
bona fide actual or potential acquisition partners, financing sources or investors and underwriters in all cases on a need to
know basis, and under appropriate confidentiality and non-use obligations (which may include professional ethical obligations) no less
stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose);
provided, however, that each Party will remain responsible for any failure by any of the foregoing recipients to treat such Confidential
Information as required under Section 8.1 as if such recipients were parties directly bound to the requirements of this Section 8.1,
(ii) as required by any court governmental body or other Governmental Authority as otherwise required by Applicable Law (including any
such disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, Pricing and Reimbursement
Approval, import authorization for any Licensed Product in the Territory, or the rules or regulations of the United States Securities
and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing
entity); provided, that, notice is promptly given to the other Party and the receiving Party cooperates with reasonable requests from
the other Party to seek a protective order or other appropriate remedy to protect the Confidential Information, or (iii) to a patent
authority as may be reasonably necessary or useful for purposes of obtaining Patents as permitted by this Agreement; provided that reasonable
measures will be taken to assure confidential treatment of such information, to the extent such protection is available. Notwithstanding
anything to the contrary contained in this ARTICLE 8, Confidential Information that is permitted or required to be disclosed will remain
otherwise subject to the confidentiality and non-use provisions of Section 8.1.2 and this Section 8.1.3. If either Party concludes that
a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar Regulatory Authority in a
country other than the United States, then such Party will, within a reasonable time (and in no event less than [***] Business Days)
prior to any such filing, provide the other Party with a copy of this Agreement showing any provisions hereof as to which the Party proposes
to request confidential treatment and will provide the other Party with an opportunity to comment on any such proposed redactions and
to suggest additional redactions. The Party filing the Agreement will take the other Party’s reasonable comments into consideration
before filing such agreement and use reasonable efforts to have terms identified by such other Party afforded confidential treatment
by the applicable Regulatory Authority.

 

    	30

     

    

 

8.2 Publicity
and Press Release. The Parties have agreed upon the content of a press release which will be issued jointly by the Parties substantially
in the form attached hereto as Schedule 8.2, promptly after the Effective Date. Except for disclosures permitted in accordance
with Section 8.1.2 or Section 8.1.3, Abeona will not issue any other public announcement, press release or other public disclosure regarding
this Agreement, its subject matter or any amendment hereto without Ultragenyx’s prior written consent, except for any such disclosure
that repeats any information regarding this Agreement, its subject matter or any amendment hereto that has already been publicly disclosed
by either Party in accordance with this Section 8.2; provided that such information remains accurate as of such time and provided the
frequency and form of such disclosure are reasonable. For clarity, Ultragenyx and its Affiliates and its and their Sublicensees will
have the right to publicly disclose research, development and commercial information (including with respect to regulatory matters) regarding
the Licensed Products; provided such disclosure is subject to the provisions of Section 8.1 with respect to Abeona’s Confidential
Information.

 

8.3 Scientific
Publications.

 

8.3.1
As between the Parties, Ultragenyx will control all scientific publications relating to all activities undertaken under this Agreement
for the relevant Licensed Products, which publications will not require the prior written approval of Abeona. If Ultragenyx or its employees
or consultants (such as clinical investigators) wish to publish or publicly present any information about a Licensed Product or the results
of any activities relating to the research or development of Licensed Products, which publication contains any of Abeona’s Confidential
Information, it will deliver to Abeona a copy of the proposed written publication or an outline of an oral disclosure at least [***]
days ([***] days in the case of abstracts) prior to submission for publication or presentation. Abeona will respond in writing promptly
and in no event later than [***] days ([***] days in the case of abstracts) after receipt of the proposed material and will have the
right to propose modifications to the publication or presentation for confidentiality reasons, or request a reasonable delay in publication
or presentation in order to protect patentable information that is Controlled by Abeona.

 

8.3.2 In
addition to the foregoing, subject to this Section 8.3, Ultragenyx will have the right at any time during and after the Term to (a) publish
the results or summaries of results of all Clinical Studies, observational studies and other studies such a meta analyses, conducted
with respect to any and all Licensed Products in any clinical trial register maintained by Ultragenyx or its Affiliates and the protocols
of such Clinical Studies on www.clinicaltrials.gov or in each case publish the results, summaries or protocols of such Clinical Studies
or other studies on such other websites or repositories or at scientific congresses and in peer-reviewed journals within such timescales
as required by Applicable Law or Ultragenyx’s or its Affiliate’s internal policies and procedures, irrespective of the outcome
of such Clinical Studies; and (b) make any other public disclosures of Clinical Data that become required of Ultragenyx due to its internal
policies and procedures or Applicable Law.

 

8.3.3 Each
publication made in accordance with this Section 8.3 will not be a breach of the confidentiality provisions set forth in Section 8.1.

 

8.4 Equitable
Relief. Given the nature of the Confidential Information and the competitive damage that could result to a Party upon unauthorized
disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a
sufficient remedy for any breach of this ARTICLE 8. In addition to all other remedies, and notwithstanding the provisions of ARTICLE
13, a Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened
breach of this ARTICLE 8.

 

ARTICLE
9

REPRESENTATIONS
AND WARRANTIES; CERTAIN COVENANTS

 

9.1 Mutual
Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Effective Date:

 

9.1.1 Organization.
It is a corporation duly organized, validly existing, and in good standing under the Applicable Law of the jurisdiction of its organization,
and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.

 

    	31

     

    

 

9.1.2 Consents.
Except for any Regulatory Approvals, manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization
of Licensed Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required
to be obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained.

 

9.1.3 No
Conflict. It is not under any obligation, contractual or otherwise, to any Person that would materially affect the performance of
obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the performance of such Party’s
obligations under this Agreement (as contemplated as of the Effective Date) and the licenses and sublicenses to be granted by such Party
pursuant to this Agreement (a) do not conflict with or violate any requirement of Applicable Law applicable to such Party, (b) do not
conflict with or violate any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently
in effect applicable to such Party, and (c) do not conflict with, violate, breach or constitute a default under, or give rise to any
right of termination, cancellation or acceleration of, any contractual obligations of such Party or any of its Affiliates.

 

9.1.4 Enforceability.
It has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance
of its obligations hereunder and this Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance
with its terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting
the availability of specific performance and other similar Applicable Law affecting the enforcement of creditors’ rights generally.

 

9.1.5 Compliance
with Applicable Law. Each Party will comply, and ensure that its Affiliates and its and their sublicensees and subcontractors comply,
in all material respects with all Applicable Laws in the performance of its obligations and exercise of its rights under this Agreement
to the extent in each case that such Applicable Law cover the performance of the relevant obligations or exercise of rights.

 

9.1.6 Authority.
(a) It has the right to grant to the other Party the licenses and sublicenses granted pursuant to this Agreement, (b) it has the right
to enter into this Agreement, and (c) the performance by such Party of this Agreement does not violate such Party’s charter documents,
bylaws or other organizational documents.

 

9.2 Additional
Representations, Warranties and Covenants of Abeona. Abeona represents and warrants as of the Effective Date, and covenants to Ultragenyx
(as applicable) that:

 

9.2.1 Licensed
Patents. Schedule 1.72 sets forth a true, correct and complete list of all Licensed Patents owned by Abeona or any of its
Affiliates as of the Effective Date. All Licensed Patents that are owned by Abeona or any of its Affiliates have been Prosecuted in good
faith in the patent offices in accordance with Applicable Law. Neither Abeona nor any of its Affiliates holds any exclusive rights to
any Patent owned by a Third Party that (i) claim the composition of matter, manufacture or use of any Licensed Product (including use
as a monotherapy or in combination with other compositions of matter), or (ii) are necessary for the research, Development, Manufacture,
import, export, use, sale or Commercialization of any Licensed Products in the Field in the Territory other than the Licensed Patents.

 

    	32

     

    

 

9.2.2 Third
Party Challenges. There are no claims, judgments, or settlements against, or amounts with respect thereto, made against Abeona or
any of its Affiliates relating to the Licensed Patents or the Upstream Patents or the Licensed Know-How. No claim or litigation has been
received by Abeona or its Affiliates or, to Abeona’s knowledge, threatened by any Person (i) alleging that any of the Licensed
Patents or Upstream Patents is invalid or unenforceable, (ii) challenging Abeona’s or its Affiliate’s Control of the Licensed
Technology (i.e., alleging that a Third Party has a right or interest in or to the Licensed Technology) or (iii) alleging misappropriation
of the Know-How of any Third Party used in the Development, Manufacture or Commercialization of Licensed Products by or on behalf of
Abeona or any of its Affiliates prior to the Effective Date.

 

9.2.3 Non-Infringement
of Third Party IP. To Abeona’s knowledge, the Development or Manufacture of Licensed Products, as conducted by Abeona, its
Affiliates or its sublicensees, or its subcontractors prior to the Effective Date did not or would not infringe any issued Patent or
misappropriate or otherwise violate or misappropriate any Know-How of any Person. No claim of infringement of the Licensed Patents or
misappropriation of the Licensed Know-How of any Third Party has been brought or asserted, or to Abeona’s knowledge, threatened,
against Abeona or any of its Affiliates with respect to the Development, Manufacture or Commercialization of Licensed Products.

 

9.2.4 Third
Party Infringement. To Abeona’s knowledge, (a) no Person is infringing or threatening to infringe or misappropriating or threatening
to misappropriate any Licensed Patents, Upstream Patents or Licensed Know-How and (b) there are no activities by Third Parties that would
constitute infringement or misappropriation of the Licensed Patents, Upstream Patents or Licensed Know-How.

 

9.2.5 Absence
of Litigation. Except as set forth on Schedule 9.2.5, there are no judgments or settlements against or owed by Abeona, its
Affiliates or its or their sublicensees, or, to Abeona’s knowledge, pending litigation against Abeona, its Affiliates, or its or
their sublicensees, or litigation threatened against Abeona, its Affiliates, or its or their sublicensees, in each case related to Licensed
Products, including any such litigation relating to any Regulatory Materials that are Controlled by Abeona, its Affiliates or its sublicensees
as of the Effective Date. Abeona hereby covenants to Ultragenyx that Abeona will timely pay all amounts due under the Settlement Agreement
described in Schedule 9.2.5.

 

9.2.6 Inventors.
Each Person who has or has had any ownership rights in or to any Licensed Patents purported to be owned solely by Abeona or any of its
Affiliates, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Licensed Patents
to Abeona or its Affiliate, as applicable.

 

9.2.7 Accuracy
of Data. All information and data provided by or on behalf of Abeona to Ultragenyx on or before the Effective Date in contemplation
of this Agreement was and is true and accurate in all materials respects.

 

9.2.8 Employment
Practices. As relevant to this Agreement: (a) neither Abeona nor any of its Affiliates has, and will not, employ child labor, forced
labor, or cruel or abusive disciplinary practices in the workplace; (b) neither Abeona nor any of its Affiliates has, and will not, discriminate
against any workers on any ground in violation of applicable Law (including race, religion, disability, gender, sexual orientation or
gender identity); and (c) Abeona and its Affiliates have paid and will pay each employee at least the minimum wage, provided and will
provide each employee with all legally mandated benefits, and has complied and will comply with all applicable Laws on working hours
and employment rights in the countries in which it operates.

 

9.2.9 Assignment
Obligations. All employees, subcontractors or consultants of Abeona or any of its Affiliates that were involved the Exploitation
of any Licensed Product prior to the Effective Date has signed a written obligation to assign to Abeona or its Affiliate, as applicable,
all rights in the Patents and Know-How that was conceived, discovered, developed or otherwise made by them in the course of such Exploitation.

 

    	33

     

    

 

9.2.10 Existing
Vendor Agreements. Abeona has not and, unless so directed by Ultragenyx, will not itself, and will cause its Affiliates not to, amend
or modify any of the terms under any of the Existing Vendor Agreements that would in any way have an adverse effect on or otherwise limit
or reduce the remedies available to Abeona or any of its Affiliates for breach of contract by the Existing Vendor under such Existing
Vendor Agreements, or otherwise adversely affect or diminish Ultragenyx’s rights or interests hereunder with respect to the Licensed
Products. Other than the Nationwide Children’s Agreement, Abeona reasonably believes as of the Effective Date that the Existing
Vendor Agreements are all the agreements to which Abeona or any of its Affiliates are a party that are material to the Exploitation of
the Licensed Products.

 

9.2.11 Nationwide
Children’s Agreement.

 

(a) The
Nationwide Children’s Agreement is the only agreement pursuant to which Abeona or any of its Affiliates acquired rights to Patents
owned by a Third Party that Cover a Licensed Product and all Licensed Know-How is owned solely by Abeona or its Affiliate;

 

(b) A
true, complete and correct copy of the Nationwide Children’s Agreement, including all amendments thereto, has been provided or
made available to Ultragenyx prior to the Effective Date and Nationwide Children’s Agreement is in full force and effect and has
not been amended, modified or waived, except as otherwise disclosed to Ultragenyx in writing prior to the Effective Date;

 

(c) To
the knowledge of Abeona, all Patents and Know-How in-licensed by Abeona pursuant to the Nationwide Children’s Agreement are free
and clear of any liens, charges and encumbrances;

 

(d) Abeona
is current on all financial obligations set forth in the Nationwide Children’s Agreement;

 

(e) Nationwide
Children’s consented to the assignment of the Nationwide Children’s Agreement to Ultragenyx; and

 

(f) No
written notice of breach, default, or termination has been received or given under Nationwide Children’s Agreement, and to the
knowledge of Abeona, there is no act or omission by Abeona or its Affiliates that would provide a right to terminate such agreement.

 

9.3 Anti-Corruption.
The Parties will comply with all applicable Laws concerning bribery, money laundering, or corrupt practices or which in any manner prohibit
the giving of anything of value to any official, agent, or employee of any government, political party, or public international organization,
candidate for public office, health care professional, or to any officer, director, employee, or representative of any other organization,
for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage, or improperly assisting
either Party in obtaining or retaining business, specifically including the U.S. Foreign Corrupt Practices Act, and the UK Bribery Act,
in each case, in connection with the activities conducted pursuant to this Agreement. Each Party will require all contractors, subcontractors,
sublicensees, and other Persons that provide services to it in connection with this Agreement to comply with such Party’s obligations
under this Section 9.3. For the avoidance of doubt the foregoing prohibited payments include facilitating payments, which are unofficial,
improper, small payments or gifts offered or made to a Government Official to secure or expedite a routine or necessary action to which
a Party is legally entitled.

 

    	34

     

    

 

9.4 No
Debarment. Each Party represents and warrants that neither it nor any of its or its Affiliates’ employees or agents performing
under this Agreement has ever been, or is currently: (a) debarred under 21 U.S.C. § 335a or by any Regulatory Authority; (b) excluded,
debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement
programs; (c) listed on the FDA’s Disqualified and Restricted Lists for clinical investigators; or (d) convicted of a criminal
offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise
declared ineligible. Each Party further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its
or its Affiliates’ employees or agents performing under this Agreement is the subject of any investigation or proceeding that could
lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such
Party will promptly notify the other Party. Abeona further covenants that if, during the Term of this Agreement, it becomes aware that
it or any of its or its Affiliates’ employees or agents who were previously involved in the Exploitation of any Licensed Product
is the subject of any investigation or proceeding that could lead to that entity becoming a debarred entity or individual, an excluded
entity or individual or a convicted entity or individual, Abeona will promptly notify Ultragenyx in writing.

 

9.5 No
Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 9, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES
OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION
OF THIRD PARTY INTELLECTUAL PROPERTY WITH RESPECT TO THE LICENSED PRODUCTS, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE.

 

ARTICLE
10

INDEMNIFICATION;
DAMAGES

 

10.1 Indemnification
by Abeona. Abeona will defend, indemnify and hold harmless Ultragenyx, its Affiliates, Sublicensees and its and their respective
directors, officers, employees and agents (each, an “Ultragenyx Indemnified Party”), from, against and in respect
of any and all Third Party Losses incurred or suffered by any Ultragenyx Indemnified Party to the extent resulting from: (a) any breach
of any representation or warranty made by Abeona in this Agreement, or any breach by Abeona or any of its Affiliates, sublicensees, or
subcontractors, or any of their respective directors, officers, employees or agents of any obligation, covenant or agreement in this
Agreement; (b) the gross negligence or willful misconduct of, or violation of Applicable Law by, Abeona or any of its Affiliates, sublicensees,
or subcontractors, or any of their respective directors, officers, employees and agents, in performing Abeona’s obligations or
exercising Abeona’s rights under this Agreement; (c) the Exploitation of the Licensed Products by or for Abeona or any of its Affiliates,
its or their sublicensees, subcontractors, agents and consultants or contractors, before the Effective Date or during the Term; (d) use
or practice of the Licensed Technology before the Effective Date or during the Term by Abeona or any of its Affiliates, sublicensees,
or subcontractors, or any of their respective directors, officers, employees or agents; provided, however, that Abeona’s obligations
pursuant to this Section 10.1 will not apply to the extent such Third Party Losses result from Third Party Losses for which Ultragenyx
has an obligation to indemnify Abeona pursuant to Section 10.2.

 

10.2 Indemnification
by Ultragenyx. Ultragenyx will defend, indemnify and hold harmless Abeona, its Affiliates and their respective directors, officers,
employees and agents (each, a “Abeona Indemnified Party”) from, against and in respect of any and all Third Party
Losses incurred or suffered by any Abeona Indemnified Party to the extent resulting from: (a) any breach of any representation or warranty
made by Ultragenyx in this Agreement, or any breach by an Ultragenyx Indemnified Party of any obligation, covenant or agreement in this
Agreement, (b) the gross negligence or willful misconduct of, or violation of Applicable Law by, an Ultragenyx Indemnified Party in performing
Ultragenyx’s obligations or exercising Ultragenyx’s rights under this Agreement, (c) the Exploitation of the Licensed Products
by or for an Ultragenyx Indemnified Party; or (d) use or practice of the Licensed Technology by Ultragenyx or any of its Affiliates or
Sublicensees; provided, however, that Ultragenyx’s obligations pursuant to this Section 10.2 will not apply to the extent such
Third Party Losses result from Third Party Losses for which Abeona has an obligation to indemnify Ultragenyx pursuant to Section 10.1.

 

    	35

     

    

 

10.3 Claims
for Indemnification. Each Party will notify the other Party in writing if it becomes aware of a claim for which such Party may seek
indemnification hereunder. If any Action (including any governmental investigation) is instituted against a Party with respect to which
indemnity may be sought pursuant to Section 10.1 or Section 10.2, as applicable, such Party (the “Indemnified Party”)
will give prompt written notice of the indemnity claim to the other Party (the “Indemnifying Party”) and provide the
Indemnifying Party with a copy of any complaint, summons or other written notice that the Indemnified Party receives in connection with
any such claim. An Indemnified Party’s failure to deliver such written notice will relieve the Indemnifying Party of liability
to the Indemnified Party under Section 10.1 or Section 10.2, as applicable, only to the extent such delay is prejudicial to the Indemnifying
Party’s ability to defend such claim. Provided that the Indemnifying Party is not contesting the indemnity obligation, the Indemnified
Party will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated
settlement or otherwise (subject to this Section 10.3) and any failure to contest such obligation prior to assuming control will be deemed
to be an admission of the obligation to indemnify. The Indemnifying Party will act reasonably and in good faith with respect to all matters
relating to such claim and will not settle or otherwise resolve such claim without the Indemnified Party’s prior written consent,
unless such settlement or resolution involves only the payment of monetary awards for which the Indemnifying Party will be fully responsible.
If the Indemnified Party has a consent right under the foregoing sentence, then such consent will not be unreasonably withheld, conditioned
or delayed and it will be reasonable to withhold, condition or delay such consent if such compromise or settlement involves (a) any admission
of legal wrongdoing by the Indemnified Party, (b) any payment by the Indemnified Party that is not indemnified under this Agreement,
or (c) the imposition of any equitable relief against the Indemnified Party. The Indemnified Party will reasonably cooperate with the
Indemnifying Party in the Indemnifying Party’s defense of any claim for which indemnity is sought under this Agreement, at the
Indemnifying Party’s cost and expense.

 

10.4 Insurance.
Each Party will maintain, at its cost, insurance or self-insurance with respect to liabilities and other risks associated with its activities
and obligations under this Agreement, in such amounts and on such terms as are customary for prudent practices for similarly situated
companies in the biotechnology or pharmaceutical industry for the activities to be conducted by such Party under this Agreement. Upon
written request, each Party will provide evidence of such insurance to the other Party and ensure that the other Party will receive no
less than [***] days’ notice of any cancelation, non-renewal or material change in such coverage.

 

ARTICLE
11

LIMITATION
OF LIABILITY

 

11.1 No
Consequential or Punitive Damages. EXCEPT AS SET FORTH IN SECTION 11.2, NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR
INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS
OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, INCLUDING ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH CASE HOWEVER CAUSED
AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE, REGARDLESS OF ANY NOTICE
OF SUCH DAMAGES.

 

    	36

     

    

 

11.2 EXCLUSION
FROM LIABILITY LIMITATION. THE LIMITATIONS AND DISCLAIMER SET FORTH IN SECTION 11.1 WILL NOT APPLY TO A CLAIM: (A) FOR GROSS NEGLIGENCE
OR WILLFUL MISCONDUCT; (B) FOR A BREACH OF ARTICLE 8; OR (C) FOR INDEMNIFIABLE LOSSES PURSUANT TO SECTION 10.1 OR 10.2.

 

ARTICLE
12

TERM
AND TERMINATION

 

12.1 Term.
Unless terminated earlier in accordance with this ARTICLE 12, this Agreement will become effective as of the Effective Date and will
continue in full force and effect, on a Licensed Product-by-Licensed Product basis, until the end of the Royalty Term for such Licensed
Product (the “Term”).

 

12.2 Paid-Up
License Upon End of Royalty Term. Upon the expiration of the Royalty Term for a given Licensed Product, the license granted to Ultragenyx
pursuant to Section 2.1 will become perpetual, irrevocable, fully paid-up, and royalty free with respect to such Licensed Product.

 

12.3 Early
Termination.

 

12.3.1 Termination
for Material Breach. Upon any material breach of this Agreement by a Party (the Party so allegedly breaching being the “Breaching
Party”), the other Party (the “Non-Breaching Party”) will have the right, but not the obligation, to terminate
this Agreement in its entirety by providing [***] days’ written notice to the Breaching Party with respect to any other breach,
which notice will, in each case (a) expressly reference this Section 12.3.1, (b) reasonably describe the alleged breach which is the
basis of such termination, and (c) clearly state the Non-Breaching Party’s intent to terminate this Agreement if the alleged breach
is not cured within the [***]-day cure period. The termination will become effective at the end of the notice period unless the Breaching
Party cures such breach during such notice period; provided, that if there is a good faith dispute with respect to the existence of a
material breach or whether such material breach has been cured, and if such alleged breach or failure to cure is contested in good faith
by the Breaching Party in writing within [***] days of the delivery of the breach notice, then the dispute resolution procedure pursuant
to ARTICLE 13, may be initiated by either Party to determine whether a material breach or a failure to cure has actually occurred. If
either Party so initiates the dispute resolution procedure, then the applicable cure period (and the corresponding termination of this
Agreement, in whole or in part), will be tolled as set forth in Section 13.2. Notwithstanding the foregoing, if the breach and failure
to cure contemplated by this Section 12.3.1 (i) is with respect to Ultragenyx’s breach of its diligence obligations set forth in
Sections 4.1 and 4.4 with respect to one or more (but not all) of the countries in the Territory or (ii) relates to some but not all
of the Licensed Products, then, in each case ((i) and (ii)), Abeona will not have the right to terminate this Agreement in its entirely,
but will have the right to terminate this Agreement solely with respect to the country(ies) or Licensed Product(s) to which such breach
and failure to cure applies.

 

12.3.2 Termination
for Bankruptcy. This Agreement may be terminated immediately, to the extent permitted by Applicable Law, by either Party upon the
filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial
portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy,
reorganization, liquidation or receivership proceeding such right to terminate will only become effective if the Party subject to such
proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] calendar days after the filing thereof.

 

12.3.3 Termination
by Ultragenyx for Convenience. Ultragenyx may terminate this Agreement in its entirety for any or no reason, upon [***] months’
prior written notice to Abeona.

 

    	37

     

    

 

12.3.4 Termination
for Safety or Efficacy. Ultragenyx may terminate this Agreement at any time in its sole discretion upon [***] days’ written
notice to Abeona in the event Ultragenyx makes a good faith determination in accordance with its standard practices and procedures for
such determinations that there is a material safety issue or efficacy concern with respect to the Licensed Products.

 

12.4 Effects
of Termination. All of the following effects of termination (but not expiration) are in addition to the other rights and remedies
that may be available to either of the Parties under this Agreement and will not be construed to limit any such rights or remedies.

 

12.4.1 Effects
of Termination Generally. In the event of any termination of this Agreement for any reason:

 

(a) Termination
of Rights and Obligations. The Parties’ rights, licenses, including any Sublicenses, and obligations under this Agreement will
terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination,
except as set forth in this Section 12.4.

 

(b) Ongoing
Clinical Studies. If at the time of such termination, any Clinical Studies for the Licensed Products are being conducted by or on
behalf of Ultragenyx, at Ultragenyx’s election, subject to patient safety and well-being, Ultragenyx will, and will cause its Affiliates
and Sublicensees to, wind down such Clinical Studies.

 

(c) Return
of Confidential Information. Each Party will, and cause its Affiliates to promptly (i) destroy all tangible items solely comprising,
bearing or containing any Confidential Information of the other Party that are in such first Party’s or its Affiliates’ possession
or control, and provide written certification of such destruction, or (ii) prepare such tangible items of the other Party’s Confidential
Information for shipment to such other Party, as such other Party may direct, at the first Party’s expense; provided, however,
that, in any event, (A) each Party may retain copies of the Confidential Information of the other Party to the extent necessary to perform
its obligations or exercise its rights that survive termination of this Agreement; and (B) each Party may retain one copy of the Confidential
Information of the other Party for archival and legal compliance purposes in accordance with standard archiving practices.

 

(d) Notwithstanding
the foregoing, if this Agreement is terminated in part with respect to a particular country or Licensed Product, then the effects of
termination will be limited to such country or Licensed Product, as applicable.

 

12.4.2 Accrued
Obligations. Termination of this Agreement for any reason will not release either Party from any obligation or liability which, on
the effective date of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination.

 

12.4.3 Survival.
The provisions set forth in the following Sections, as well as, to the extent applicable, any other Sections or defined terms referred
to in such Sections or Articles or necessary to give them effect, will survive the expiration or termination of this Agreement in its
entirety: ARTICLE 6 (but only with respect to payments accrued thereunder prior to termination), ARTICLE 7 (with respect to the provisions
regarding Joint Patents), ARTICLE 8, ARTICLE 10, ARTICLE 11, ARTICLE 13, ARTICLE 14, Sections 2.8, 7.1, 7.5, 12.2, and this Section 12.4.
Furthermore, any other provisions required to interpret the Parties’ rights and obligations under this Agreement, including applicable
definitions in ARTICLE 1, will survive to the extent required.

 

    	38

     

    

 

ARTICLE
13

DISPUTE
RESOLUTION

 

13.1 Dispute
Resolution. Except as otherwise expressly set forth in this Agreement, disputes of any nature arising under, relating to, or in connection
with this Agreement (“Disputes”) will be resolved pursuant to this ARTICLE 13.

 

13.2 Tolling.
The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches), as well as all time
periods in which a Party must exercise rights or perform obligation hereunder, will be tolled once the Dispute resolution procedures
set forth in this ARTICLE 13 have been initiated and for so long as they are pending, and the Parties will cooperate in taking all actions
reasonably necessary to achieve such a result. Further, with respect to any time periods that have run during the pendency of the Dispute,
the applicable Party will have a reasonable period of time or any specific timeframe established by the tribunal’s decision to
exercise any rights or perform any obligations affected by the running of such time periods.

 

13.3 Informal
Dispute Resolution; Escalation to Chief Executive Officers. In the event of any Dispute,
the Parties will first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. If, after [***]
Business Days from receipt of the written notice of a Dispute, such Dispute has not been resolved on an informal basis, either Party
may refer any Dispute to the Chief Executive Officers of the Parties (the “Executive Officers”) by delivering written
notice to the other Party, who will confer in good faith on the resolution of the issue for a [***]-day period following receipt of such
written notice. If the Chief Executive Officers are unable to resolve any such Dispute within such [***] day period, then either Party
may refer such Dispute for Expedited Arbitration in accordance with Section 13.4.

 

13.4 Expedited
Arbitration. Except as otherwise expressly set forth in this Agreement, in the event the Parties have not resolved a Dispute within
[***] days of receipt of the written notice referring such Dispute to the Executive Officers, then the Parties will follow the expedited
dispute resolution process in this Section 13.4 (“Expedited Arbitration”). The Parties agree and acknowledge that
any good faith dispute under Expedited Arbitration (“Expedited Dispute”) will not be deemed to be a material breach
of this Agreement. The Expedited Dispute will be submitted to fast-track, binding arbitration in accordance with the following:

 

13.4.1 Arbitration
will be conducted in New York, New York under the Expedited Procedures of the Commercial Arbitration Rules of the American Arbitration
Association (the “AAA”) for the resolution of commercial disputes in the most expedited manner permitted by such rules.
The Parties will appoint a single arbitrator to be selected by mutual agreement. If the Parties are unable to agree on an arbitrator,
the Parties will request that the AAA select the arbitrator. The arbitrator will be a professional in business or licensing experienced
in the valuation of biopharmaceutical products with at least ten (10) years of experience in the pharmaceutical and life sciences industries,
including the conduct of research, development and commercialization collaborations. The AAA fees associated with the arbitration will
be borne equally by the Parties, and each Party shall bear its own attorneys’ fees and costs. Except in a proceeding to enforce
the results of the arbitration or as otherwise required by Applicable Laws, neither Ultragenyx nor Abeona nor any arbitrator may disclose
the existence, content or results of any arbitration hereunder without the prior written agreement of Ultragenyx and Abeona.

 

13.5 Patent
Disputes. Notwithstanding Section 13.4, any dispute, controversy or claim relating to the inventorship, scope, validity, enforceability
or infringement of any Patents Covering the Exploitation of any Licensed Product will be submitted to a court of competent jurisdiction
in the country in which such Patents were granted or arose. The sole venue for any dispute regarding a United States patent shall be
the United States District Court for the District of Delaware.

 

    	39

     

    

 

13.6 Injunctive
Relief. Notwithstanding the dispute resolution procedures set forth in this ARTICLE 13, in the
event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining
orders, specific performance or other injunctive relief), without first submitting to any dispute resolution procedures hereunder or
posting any bond.

 

ARTICLE
14

MISCELLANEOUS

 

14.1 Assignment;
Successors.

 

14.1.1 Assignment.
This Agreement and the rights and obligations of each Party under this Agreement will not be assignable, delegable, transferable, pledged
or otherwise disposed of by either Party without the prior written consent of the other Party; provided, however, that either Party may
assign or transfer this Agreement together with all of its rights and obligations hereunder, without such consent (but with written notice
to the other Party within [***] days of such assignment or transfer), (A) to an Affiliate or (B) subject to Section 2.6 in the case of
Abeona, to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which
this Agreement relates, or in the event of its merger or consolidation, reorganization or similar transaction, subject to the assignee
agreeing in writing to be bound by the terms and conditions of this Agreement. Any assignment in violation of this Section 14.1.1 will
be null and void.

 

14.1.2 Successors.
Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure to the benefit of
and be enforceable by and against, the successors and permitted assigns of the assigning Party. The permitted assignee or transferee
will assume all obligations of its assignor or transferor under this Agreement. Any assignment or attempted assignment by either Party
in violation of the terms of this Section 14.1.2 will be null, void and of no legal effect.

 

14.2 Governing
Law. This Agreement will be governed by and interpreted under the laws of the State of New York, without regard to the conflicts
of law principles thereof. The Parties agree to exclude the application to this Agreement of the United Nations Conventions on Contracts
for the International Sale of Goods (1980).

 

14.3 Notices.
All communications hereunder will be in writing or by electronic mail, and will be deemed to have been duly given (a) upon personal delivery,
(b) upon deposit with a recognized courier with next-day delivery instructions, or (c) one Business Day after sending, if sent by electronic
mail and no delivery failure notification has been received. This Section 14.3 is not intended to govern the day-to-day business communications
necessary between the Parties in performing their obligations under the terms of this Agreement.

 

    	40

     

    

 

	If to Abeona:	Abeona
    Therapeutics Inc.

    6555
    Carnegie Avenue, 4th Floor

    Cleveland,
    OH 44103

    Attention:
    Scott D. Nogi, Head of Business Operations

    Email:
    [***]

     

    Abeona
    Therapeutics Inc.

    1330
    Avenue of the Americas, 33rd Floor

    New
    York, NY 10019

    Attention:
    Brendan M. O’Malley, General Counsel

    Email:
[***] and

      [***]

	 	 
	With copies to:	Cooley
    LLP

    500
    Boylston Street

    14th
    Floor

    Boston,
    Massachusetts 02116

    Attention:
    Geoffrey Spolyar

    Email:
    [***]

	 	 
	If to Ultragenyx:	Ultragenyx
    Pharmaceutical Inc.

    60
    Leveroni Court

    Novato,
    CA 94949

    Attention:
    Chief Business Officer

    Email:
    [***]

	 	 
	With copies to (which will not constitute notice to):	Goodwin
    Procter LLP

    100
    Northern Avenue

    Boston,
    Massachusetts 02210

    Attention:
    Kathleen Kean

    Telephone:
    [***]

    Email:
    [***]

 

14.4 Severability.
In the event that one or more provisions of this Agreement is held invalid, illegal or unenforceable in any respect, then such provision
will not render any other provision of this Agreement invalid or unenforceable, and all other provisions will remain in full force and
effect and will be enforceable, unless the provisions that have been found to be invalid, illegal or unenforceable will substantially
affect the remaining rights or obligations granted or undertaken by either Party. The Parties agree to attempt to substitute for any
invalid or unenforceable provision a provision which achieves to the greatest extent possible the objectives of the invalid, illegal
or unenforceable provision.

 

14.5 Integration.
This Agreement and the Assignment Agreement, together with all schedules and exhibits attached hereto and thereto, constitutes the entire
agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements between the
Parties with respect to the subject matter hereof, whether written or oral, including, effective as of the Effective Date, the Prior
CDA (provided that all information disclosed or exchanged under such agreement will be treated as Confidential Information hereunder).
In the event of a conflict between any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other
hand, the terms of this Agreement will govern. Each Party confirms that it is not relying on any representations or warranties of the
other Party except as specifically set forth in this Agreement.

 

    	41

     

    

 

14.6 Waivers
and Amendments. The failure of any Party to assert a right under this Agreement or to insist upon compliance with any term or condition
of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition
by the other Party. The exercise by any Party of any right or election under the terms or covenants herein will not preclude or prejudice
any Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding
taken by the Parties hereunder. Notwithstanding the authority granted to the Joint Transition Team under this Agreement, (a) no waiver
will be effective unless it has been given in writing and signed by an authorized representative of the Party giving such waiver, and
(b) no provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of
each Party.

 

14.7 Independent
Contractors; No Agency. Neither Party will have any responsibility for the hiring, firing or compensation of the other Party’s
or such other Party’s Affiliates’ employees or for any employee benefits with respect thereto. No employee or representative
of a Party or its Affiliates will have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or
to create or impose any contractual or other liability on such other Party, without such other Party’s written approval. For all
purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party’s legal relationship under this
Agreement to the other Party will be that of independent contractor, and the relationship between the two Parties will not constitute
a partnership, joint venture, or agency, including for all tax purposes, except as otherwise required by Applicable Law.

 

14.8 Affiliates,
Sublicensees, and Subcontractors. To the extent that this Agreement imposes obligations on Affiliates, Sublicensees or subcontractors
of a Party, such Party will cause its Affiliates and its and their sublicensees and subcontractors to perform such obligations, as applicable.
Either Party may use one or more of its Affiliates, its or their sublicensees or subcontractors to perform its obligations and duties
or exercise its rights under this Agreement, solely to the extent permitted and as specified in this Agreement; provided, however, that
(a) each such Affiliate, Sublicensee or subcontractor will perform any such obligations delegated to it in compliance with the applicable
terms and conditions of this Agreement as if such Affiliate, Sublicensee or subcontractor were a party hereto, (b) the performance of
any obligations of a Party’s by its Affiliates, its or their sublicensees or subcontractors will not diminish, reduce or eliminate
any obligation of such Party under this Agreement, (c) the Party using such contractor will terminate promptly any subcontractor, and
will give the other Party notice of such termination, in the case of any material breach of this Agreement by such subcontractor and
(d) subject to such Party’s assignment to an Affiliate pursuant to Section 14.1, such Party will remain liable under this Agreement
for the prompt payment and performance of all of its obligations under this Agreement. Subject to this Section 14.8, if a Party exercises
its rights and performs its obligations under this Agreement through one or more of its Affiliates, “Abeona” will be interpreted
to mean “Abeona or its Affiliates” and “Ultragenyx” will be interpreted to mean “Ultragenyx or its Affiliates”
where necessary to give each Party’s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability
to perform its obligations under this Agreement.

 

14.9 No
Third Party Beneficiary Rights. The representations, warranties, covenants and agreements set forth in this Agreement are for the
sole benefit of the Parties and their successors and permitted assigns, and they will not be construed as conferring any rights on any
other Third Party. This Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including
any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated
hereby, other than, to the extent provided in ARTICLE 10, the Indemnified Parties.

 

    	42

     

    

 

14.10 Non-exclusive
Remedy. Except as expressly provided herein, the rights and remedies provided herein are cumulative and each Party retains all remedies
at law or in equity, including each Party’s ability to receive legal damages or equitable relief, with respect to any breach of
this Agreement. Neither Party will be required (but, for clarity, will have the right as specified in this Agreement) to terminate this
Agreement due to a breach of this Agreement by the other Party.

 

14.11 Interpretation.
The Article and Section headings used herein are for reference and convenience only, and will not enter into the interpretation of this
Agreement. Except as otherwise explicitly specified to the contrary, (a) references to an Article, Section or Exhibit means an Article
or Section of, or a Schedule or Exhibit to this Agreement and all subsections thereof, unless another agreement is specified; (b) references
in any Section to any clause are references to such clause of such Section; (c) references to any agreement, instrument, or other document
in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced,
or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto;
(d) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the
then-current amendments thereto or any replacement or successor law, rule or regulation thereof; (e) words in the singular or plural
form include the plural and singular form, respectively; (f) unless the context requires a different interpretation, the word “or”
has the inclusive meaning that is typically associated with the phrase “and/or”; (g) the terms “including,” “include(s),”
“such as,” “e.g.” and “for example” mean including the generality of any description preceding such
term and will be deemed to be followed by “without limitation”; (h) whenever this Agreement refers to a number of days, such
number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day
or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (i) “monthly”
means on a calendar month basis, (j) “quarter” or “quarterly” means on a Calendar Quarter basis; (k) “annual”
or “annually” means on a Calendar Year basis; (l) “year” means a 365 day period unless Calendar Year is specified;
(m) references to a particular Person include such Person’s successors and assigns to the extent not prohibited by this Agreement;
(n) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be
deemed to include the plural (and vice versa); (o) a capitalized term not defined herein but reflecting a different part of speech than
a capitalized term which is defined herein will be interpreted in a correlative manner; (p) any definition of or reference to any agreement,
instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein);
(q) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement
(including any Exhibits or Schedules); (r) neither Party or its Affiliates will be deemed to be acting “on behalf of” the
other Party under this Agreement, except to the extent expressly otherwise provided; (s) provisions that require that a Party, or the
Joint Transition Team hereunder “agree”, “consent” or “approve” or the like will be deemed to require
that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as
expressly provided herein, excluding instant messaging; and (t) the word “shall” will be construed to have the same meaning
and effect as the word “will”.

 

14.12 Further
Assurances. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do
and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments,
as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the
provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement (including
working collaboratively to correct and clerical, typographical, or other similar errors in this Agreement).

 

    	43

     

    

 

14.13 Ambiguities;
No Presumption. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by
and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained
herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly,
in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording
or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement will not be construed against any Party
under the rule of construction, irrespective of which Party may be deemed to have authored the ambiguous provision.

 

14.14 Execution
in Counterparts; PDF Signatures. This Agreement may be executed in counterparts, each of which counterparts, when so executed and
delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument
even if both Parties have not executed the same counterpart. Signatures provided in AdobeTM Portable Document Format (PDF) sent
by electronic mail will be deemed to be original signatures.

 

14.15 Export
Control. This Agreement is made subject to any restrictions required by Applicable Law concerning the export of products or technical
information from the U.S. or other countries which may be imposed upon or related to the Parties from time to time. Each Party agrees
that it will not export, directly or indirectly, any technology licensed to it or other technical information acquired from the other
Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires
an export license or other governmental approval, except in compliance with U.S. export laws and regulations.

 

[Remainder
of this page intentionally blank.]

 

    	44

     

    

 

IN
WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized representative on the Effective Date.

 

	 	ABEONA THERAPEUTICS
    INC.
	 	 	 
	 	/s/ Vishwas Seshadri
	 	Name:	Vishwas Seshadri
	 	Title:	President and CEO
	 	 	 
	 	ULTRAGENYX PHARMACEUTICAL
    INC.
	 	 
	 	/s/ Emil Kakkis
	 	Name:	Emil Kakkis
	 	Title:	CEO

 

[Signature
Page to License Agreement]

 

    	 

    	 

    

 

Schedule
1.42

 

Existing
Vendor Agreements

 

    	 

    	 

    

 

Schedule
1.72

 

Licensed
Patents

 

    	 

    	 

    

 

Schedule
3.1.2

 

Transition
Plan

 

    	 

    	 

    

 

Schedule
3.1.4

 

Transition
Costs

 

    	 

    	 

    

 

Schedule
3.2

 

Initial
Transfer of Licensed Know-How

 

    	 

    	 

    

 

Schedule
4.1.3

 

Prior
Development Costs

 

    	 

    	 

    

 

Schedule
8.2

 

Form
of Press Release

 

    	 

    	 

    

 

Schedule
9.2.5

 

Absence
of Litigation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]